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ABSTRACT 
This study evaluated vaccinia-vectored vaccines expressing glycoproteins gB, gC, or 
gD of pseudorabies virus (PRV) in pigs. The vaccines are based on an attenuated vaccinia 
virus strain, NYVAC, which has reduced virulence and replicative capacity for certain species, 
including swine. The recombinant vaccinia vaccines were unable to prevent replication of 
virulent pseudorabies virus or latency but they were able to decrease the amount of virus shed 
after challenge and decrease clinical signs. In particular, pigs vaccinated with the recombinants 
expressing either gB or gD were protected at a level comparable to an inactivated PRV virus 
that was given for comparison. No lesions or clinical signs were seen following vaccination in 
these studies and no seronegative pigs in contact with vaccinia-vaccinated pigs ever 
seroconverted. No significant increase in protection occured by giving recombinants 
expressing multiple glycoproteins and there was no virus neutralizing antibody response or 
protection induced when the recombinant vaccines were given orally or intranasally. The 
response to the recombinants is dose dependent but there was no indication that prior immunity 
to the vaccinia parent virus had any inhibitory effect on subsequent vaccination with these 
recombinants. The gB recombinant, but not the gD recombinant, was able to stimulate an 
active immune response in piglets with passive immunity fix)m PRV or NYVAC/gD vaccinated 
dams. The NYVACyPRV recombinant vaccines were compatible with differential serologic 
tests currently on the market We could not demonstrate significant cell-mediated immune 
responses after vaccination with the recombinant vaccines but they may prime this type of 
response. In summary, the NYVAC/PRV recombinant vaccines afforded protection 
comparable with that of PRV vaccines currentiy on the market, were safe, and offer some 
advantages over currentiy available vaccines such as elimination of attenuated PRV viral 
strains, better induction of immunity in the presence of passive immunity, and more sensitive 
differential testing capabilities. 
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CHAPTER 1. GENERAL INTRODUCTION 
Introduction 
Pseudorabies (PR), also known as Aujeszky's disease, is an economically important 
viral disease of swine worldwide. Its financial impact is an accumuladon of expenses 
associated with disease prevention, such as vaccination, and the losses of production 
associated with clinical disease. The consequences of infection depend on the interplay of a 
variety of factors reflecting both host susceptibility and vims virulence and range fix)m acute 
illness and death to subclinical infection and immunity. Seropositive status of herds has also 
been associated with increased respiratory disease leading to speculation that PR predisposes to 
secondary infections. In pigs which survive initial infection, a latent form of the virus persists 
and can under certain conditions be reactivated and shed back into the environment 
Since the early 1970's the incidence of pseudorabies in the United States and elsewhere 
has increased markedly in concert with the increase in confinement housing of swine. This led 
to the implementation in this country of a national pseudorabies eradication program which was 
started in 1989 and is targeted for completion in the year 2000. Efforts have been made to 
identify all of the infected herds in the United States and then through a combination of control 
measures, which in many cases includes intensive vaccination, to rid each of these herds of 
infection. The eradication program in the United States and several similar programs in 
westem Europe have stimulated a burst of supportive research activities, especially in regard to 
improved vaccines, epidemiology, and a better fundamental understanding of both protective 
immunity and viral latency. Both attenuated and inactivated "marker" vaccines are on the 
itiarket which have at least one nonessential gene deleted firom the genome so that vaccinated 
pigs can be differentiated &om naturally infected individuals. Although vaccines protect 
against clinical disease and decrease shedding of virus, no vaccine has been able to prevent 
acute infection or latency. 
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A new concept of using vectored vaccines may retain the benefits of live vaccines yet 
eliminate the use of disease causing virus. Genes firom a pathogenic virus can be inserted into 
a vector virus genome, such as vaccinia virus, through generic engineering. When the 
recombinant veaored virus is given to an animal it replicates and produces the antigenic 
proteins of the disease causing virus which can then stimulate the immune system. The 
antigens important in stimulating a protective immune response to a given pathogen, whether 
cell-mediated, humoral or both, must be known for this approach to be effective. The use of 
vaccinia or other viral vectors as vaccine carriers has advantages. One is avoiding the use of 
the disease causing virus in immunizing the animal, only the significant immunogenic antigens 
need be used. Yet, since it is a live viral vector it may be able to stimulate cellular immune 
responses better than a killed or subunit vaccine. In addition, the large genome of pox viruses 
makes it possible to clone in significant amounts of genetic material which facilitates the design 
of multivalent vaccines. Possibilities for differential testing, which do not have to rely on a 
single differential antigen test are great The success of using vaccinia in the eradication of 
small pox is largely due to its stability in the field, ease of administration and ease and low cost 
with which it can be produced. The use of vaccinia as expression vectors for genes also offers 
advantages for basic science research. They can be used to determine the fimction of gene 
products and study immune responses to individual or combinations of viral proteins. There 
have been questions raised about the use of vaccinia-vectored vaccines as well, including 
possible health risks to humans. Some of this concem can be alleviated through the use of 
strains of vaccinia that have been attenuated. Another question left to answer is whether or not 
a vaccinia vectored vaccine can elicit an immune response comparable with that of more 
traditional vaccines. 
Recentiy, a novel vaccinia virus strain was developed with highly attenuated 
characteristics compared to existing vaccinia virus vaccine strains. NYVAC was the 
designation given to this highly attenuated vaccinia virus vector derived by genetically 
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engineeiing the deletion of putative virulence and host range genes &om the Copenhagen 
vaccinia virus vaccine strain. NYVAC has debilitated growth properties in cells derived fix)m a 
number of species, including swine and humans, but retains full replicative capacity in accepted 
cell substrates for vaccine production such as primary chick embryo fibroblasts. 
Noting the advantages of recombinant vaccinia vaccines for a disease such as PR, for 
which there is an ongoing eradication program, combined with the safety feamres of the 
NYVAC strain of vaccinia, a plan was devised to test the effectiveness of recombinant 
NYVAC/pseudorabies virus (PRV) vaccines in protecting pigs fix)m virulent pseudorabies 
virus infection. The objectives were to evaluate whether or not recombinant NYVAC/PRV 
vaccines would be able to stimulate a protective immune response in swine, determine what 
immunogen or combination of immunogens of pseudorabies in this vector would be most 
effective at stimulating a protective response, determine if NYVAC/PRV vaccines would be 
effective at stimulating an active immune response in the presence of passively acquired 
maternal antibody, and lastiy to determine if the NYVAC/PRV vaccines were capable of 
inducing a cell-mediated immune response. 
Dissertation organization 
This dissertation begins with a general introduction containing the literature review. 
Following the general introduction axe five manuscripts. The first, published in Veterinary 
Microbiology, is entided "Vaccination of pigs against pseudorabies with highly attenuated 
vaccinia (NYVAC) recombinant viruses." The second, published in The Canadian Journal of 
Veterinary Research, is a brief communication entided "Comparison of the protective response 
induced by NYVAC vaccinia recombinants expressing either gp50 or gll and gp50 of 
pseudorabies virus." The third and fourth papers have been submitted to Veterinary 
Microbiology dsid Research in Veterinary Science, respectively, and address aspects of 
vaccination in the presence of matemal immunity. They are entitled "Vaccination with 
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recombinant vaccinia virus vaccines expressing glycoproteins of pseudorabies virus in the 
presence of maternal immunity" and "Successful pseudorabies vaccination in maternally 
immune piglets using recombinant vaccinia virus vaccines." The final manuscript has been 
prepared for submission to Veterinary Immunology and Immunopathology and reports on 
studies evaluating cell-mediated immunity. A general conclusion section follows the 
manuscripts. Six appendices follow the general conclusion section which contain tables of 
additional experimental data that may aid in interpreting the general discussion. The references 
cited in the general introduction and general conclusion sections are listed after the appendices. 
Susan Brockmeier was the principle investigator on each of the manuscripts. William 
Mengeling and Michael Wannemuehler were co-major professors serving in an advisory role. 
James Tartaglia, Michel Riviere and Enzo Paoletti contributed the cloning of PRV 
glycoproteins genes into the NYVAC vector described in the first manuscript Kelly Lager 
contributed to the experimental design and execution of some of the experiments. 
Literature Review 
Pseudorabies (PR), also known as Aujeszky's disease, was first recognized as a 
disease in species other than swine, because in most other species it nearly always results in a 
fatal encephalitis. Early descriptions of pseudorabies-like disease in cattle and dogs were 
reported in the 1800's [92]. The initial characterization of the disease by Aujeszky describing 
the differences between PR and rabies was done in 1902 [8]. The disease in cats, dogs, cattie 
and sheep became known as "mad itch" and eventually these fatal infections were 
epidemiologically linked with the presence of swine and swine were shown to be the reservoir 
for the virus [252]. Pseudorabies has a nearly worldwide distribution and is a major economic 
problem in most of the densely swine-populated areas of the world. 
Pathogenesis. Transmission of pseudorabies virus (PRV) occurs largely through the 
oronasal route. Although much of the spread is probably by close contact there have been 
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reports of long distance aerosol spread [49,50]. Replication initially occurs in the tissues of 
the upper respiratory tract and oropharyngeal region and can cause acute necrotizing rhinitis, 
pharyngitis and tonsillitis with mononuclear cell infiltrates [10,12,56, 169,200,206,244, 
294]. Virus also infects nerve endings and is transported centripitally through the axon to the 
nerve ganglia and then by trans-synaptic cell-to-cell spread to higher order neurons in the brain 
resulting in ganglioneuritis and encephalitis and in some cells a nonproductive latent infection 
[64,167,169,199,244,294]. Viral infection can extend to the lower respiratory ttact and 
cause an interstitial pneumonia and infection of the alveolar macrophages [10,51,201, 294]. 
Draining lymph nodes become infected and a low level viremia ensues in which much of the 
virus is cell-associated with monocytes. This is one method by which the virus can become 
ttansplacentally transmitted in pregnant females [202,294]. Hematogenous spread to other 
organs can occur and foci of infection can be found in many internal organs resulting in focal 
areas of necrosis and inflammation [169,198,243, 244,294]. Infection of the reproductive 
tract can occur through intravaginal infection from boars shedding virus in their semen leading 
to reproductive failure. Infection of the reproductive tract causes ulcerative vaginitis and 
endometritis and necrotic and inflammatory lesions of the corpora lutea which may interfere 
with implantation or maintenance of pregnancy and PRV can infect preimplantaion embryos 
resulting in early embryonic death [26,27]. Virus is shed through the oral and nasal secretions 
as early as 24 hours after initial infection, prior to the development of clinical signs, and often 
continues for 2 weeks [294]. The distribution of virulent virus in vaccinated animals is much 
the same, although the titer of virus may be lower and infection of higher order neurons may be 
limited [294]. 
The severity of PR depends upon species, age, virulence of the viral strain, immune 
status of the host, infecting dose and route of viral infection [128]. In swine, piglets are the 
most severely affected by the disease and the outcome of infection is often fatal in suckling 
piglets receiving no PRV specific maternal immunity. The first clinical signs usually develop 
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24 to 48 hours after infection and are respiratory in nature, characterized by sneezing, coughing 
and fever. After this, piglets usually become depressed and anorectic and it is not unusual to 
see excessive salivation and vomiting. Two to 5 days after initial signs, neurologic signs may 
develop including tremors, head tilt and seizures which often progress to coma and death. As 
pigs become older, they become less susceptible to disease. Infection of manure pigs may 
cause respiratory signs, or be subclinical but leave the host more susceptible to secondary 
infections. Pseudorabies virus can also cross the placenta and result in death of fetuses at any 
stage of development The results of fetal infection depend on the stage of gestation, with 
resorption and return to estms resulting early in gestation or abortion or delivery of variable 
numbers of stillborn, or macerated fetuses observed at the latter stages of gestation [26,27,55, 
97,129,297]. Swine that survive initial infection often, if not always, become latendy 
infected carriers of PRV and thus serve as primary reservoirs. Other animals such as dogs, 
cats, cattie, sheep, goats and many wild animals, including mice and rats, are also susceptible 
to infection with PRV but infection almost always results in a fatal encephalitis. While these 
"dead end hosts" may be short term carriers of the virus, they appear to be of relatively litde 
importance in the epidemiology of the disease [128]. Importantiy, seropositive feral swine are 
prevalent in some areas of the United States which could be a source of infection for domestic 
herds [222,273]. Horses and birds are relatively resistant to infection and humans are a 
notable exception to susceptibility to PRV [128]. 
Diagnosis of the disease can be through clinical presentation, virus isolation, 
identification of viral antigen in tissues through fluorescent antibody staining, and serology 
[128]. With the eradication programs present in many countries identification of pseudorabies 
infected herds is commonly acheived through serologic surveillance. 
Immunosuppression. As stated previously, PRV infection in finishing or breeding 
age swine is often subclinical or causes only mild respiratory signs, but it may be a 
predisposing factor for more severe bacterial pneumonias in pigs. Studies in which 
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experimental infection with PRV was followed by challenge with Pasteurella multocida. 
Streptococcus suis or Actinobacillus pleuropneumoniae showed significantly increased 
pneumonic lesions when both pathogens were given versus either PRV or the bacteria alone 
[79, 102, 245]. 
PRV infects, replicates in, and kills alveolar macrophages (AM) [99]. Studies have 
also shown that AM fiinction is impaired after they are infected with PRV. Antibody-
dependent phagocytosis was decreased, phagosome-lysosome fusion was depressed and O2 
release was reduced in AMs infected with PRV [100,101]. Also, the ability to kill Pasteurella 
multocida was decreased in PRV infected AM [78]. This has led to the consideration that PRV 
immunosuppresses the host by impairment of innate defense mechanisms against bacterial 
infection in the lungs, namely clearance by AM 
The effects of PRV on peripheral blood mononuclear cells (PBMC), which is the 
fraction of circulating cells composed of monocytes and lymphocytes, has also been studied. 
Monocytes appear to be the main cell type within which PRV replicates. The proportion of 
monocytes infected ranges from 26% to 100% in different reports and may depend on isolation 
and cultivation techniques prior to infection [46,194,203]. Reports indicate that PRV infects 
lymphocytes also, but the evidence for this is less clear cut and most smdies indicate low level 
infections. One study reports marginal titer increases when PBMC enriched for lymphocytes 
were infected with PRV, but there was no loss of ceU viability [46]. The authors also reported 
that proliferation and IL-2 production in response to concanavalin A stimulation was 
suppressed in lymphocyte cultures infected with PRV in vitro [46]. Pseudorabies virus 
infection in vivo also decreased lymphocyte proliferation in response to concanavalin A and IL-
2 production in pigs [73]. Another study reported a low level productive infection in PBMC 
enriched for lymphocytes only in mitogen stimulated cells and not in resting cells [209]. This 
study detected virus in peripheral blood lymphocytes from infected pigs by cocultivation with 
PK-15 cells. Virus was detected after 5 to 7 days possibly indicating virus was present in a 
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latent state or intracellularly requiring lysis of the cells [209]. Only about 0.5% of B and T 
lymphocytes were infected in another study [203]. In contrast, another group was able to 
demonstrate PRV replication in both lymphocyte and monocyte cultures with about 50% of B 
ceUs and 25% of CD4''" and CDS'*" T cells infected. This group also found that addition of 
concanavalin A restored the replication of a TK- mutant of PRV but reduced the replication of 
wild type PRV [194]. Effects of PRV infection on PBMC may be another way PRV 
immunosuppresses the host and predisposes to secondary infections. 
PRV down regulated major histocompatibility complex (MHC) class I antigen 
production in certain murine and porcine cell lines but increased MHC class I and II antigen 
expression in a porcine immortalized B cell line possibly in response to interferon production 
which is another method by which PRV may modulate the immune response[120,173]. 
Molecular Biology. Pseudorabies virus belongs to the genus Varicellovirus, 
subfamily Alphaherpesvirinae in the family of viruses known as Herpesviridae [180]. Its 
official taxonomic name is Suid Herpesvirus 1 but it is commonly known as pseudorabies 
virus or Aujeszky's disease virus. Pseudorabies virions are approximately 180 nm in diameter 
and are composed of an icosahedral capsid surrounded by a layer of globular protein known as 
the tegument and enclosed in a envelope which has glycoprotein peplomers. The genome is 
composed of linear, double stranded DNA which is approximately 150 kbp, GC rich (73%) 
and encodes at least 70 proteins [180]. It is composed of a unique long (UL) segment, and a 
unique short (US) segment which is flanked by inverted repeat segments[20]. The gene 
aiiangement of viruses belonging to this subfamily are generally colinear and there is 
homology among the amino acid sequences of many of the gene products [21,180]. Because 
of this, the nomenclature of PRV genes is being changed to reflect homology with genes of 
herpes simplex virus. 
Pseudorabies virus replicates in cell cultures from many species. Cytopathic effect seen 
in cell culture appears as rounded cells and areas of lysis in foci of infection. Syncytial 
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fonnadon is seen in some cell types, with some strains of the virus. The infectious cycle 
begins with attachment and ends with lysis of the cell and usually takes 15 - 24 hours. The 
infectious cycle begins with adsorption of herpes virus to cell receptors via glycoprotein 
peplomers. With pseudorabies, the gC glycoprotein is at least partially responsible for this step 
attaching to heparan moieties on the cell surface [189,246]. Penetration of the nucleocapsid 
into the cytoplasm occurs through fusion of the envelope with the cell membrane which is 
mediated by glycoprotein peplomers gB, gD and gH [214,215,227]. The capsid is 
subsequently transported to the nuclear pores where the viral DNA is released into the nucleus. 
Transcription of mRNA utilizes host RNA polymerase n with the participation of viral factors 
and precedes in an ordered cascade type fashion [71]. Immediate early genes are transcribed 
first and do not require de novo protein synthesis. There is only one immediate-early gene 
(IE 180) in PRV and it is essential for PRV replication. Functional IE 180 polypeptides 
transactivate early and late PRV genes and repress transcription of its own gene [41,282]. 
IE 180 is a homolog of the herpes simplex virus type 1 (HSV-1) ICP4 polypeptide. 
Transcription of early genes, which requires IE 180 synthesis, occurs before viral DNA 
synthesis and some of these genes encode proteins which along with cellular factors are used 
in a rolling circle mechanism of viral DNA replication. Transcription of late genes occurs after 
the onset of viral DNA synthesis and many of these genes encode stmctural proteins of the 
virus. Assembly of new capsids occurs in the nucleus where encapsidated viral DNA 
associates with altered areas of the inner layer of the nuclear membrane and buds through this 
membrane to obtain its envelope. 
Glycoproteins. Glycoprotein peplomers which stick out from the envelope cany out 
important functions for the virus. There are at least eleven glycoproteins produced by PRV 
which are as follows (old terminology in parentheses): gB(gII), gC(gIII), gD(gp50), gE(gI), 
gG(gX), gH, gl(gp63), gK, gL, gM and gN. Glycoproteins gB, gD, gH and gL are known to 
be essential for viral replication and although gC, gE, gG, and gl can be deleted, the fact that 
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no field isolates have been found which lack these glycoproteins suggests an important role in 
the biology of the virus in vivo. Genes for glycoproteins gD, gE, gG and gl are found in the 
unique short segment of the genome while gB, gC, gH, gK, gL, gM and gN are found in the 
unique long segment [110, 130, 131, 181, 184, 220, 230, 236, 285]. 
Glycoproteins gE (130 kDa) and gl (63 kDa) form a noncovalent functional complex 
and the genes encoding these proteins are located adjacent to each other in the short unique 
segment of the genome [221,311]. This complex in pseudorabies does not appear to have Fc 
receptor activity as it does with herpes simplex virus [311]. The virus is still capable of 
replication without them, but deletions of these glycoproteins reduce the virulence of the virus 
[119, 124, 126, 182, 183, 185, 186, 187,188]. Deletion of two amino acids from gE was 
able to decrease virulence and neurotropism but not affect immunogenicity of wild-type virus 
[107]. Glycoprotein gE appears to facilitate the spread of virus through the central nervous 
system because mutants lacking this glycoprotein do not infect higher order neurons like wild 
type virus [69, 70,107, 126, 138, 139,140, 193]. Part of the reason for lessened 
neuroinvasiveness may be the fact that glycoproteins gE and gl along with gC have been 
associated with viral release from infected cells [186,250]. Glycoprotein gE has also been 
shown to promote cell fusion and virus spread through direct cell-to-ceU transmission [308] 
and may be involved in axonal anterograde transport [138]. Strains with altered expression of 
gE can spontaneously occur in vivo and in vitro [185]. Passage of PRV in chick embryo 
fibroblasts promotes loss of part of the unique short segment of the genome which contains the 
gE gene. Lack of expression of gE appears to give these strains a growth advantage in these 
cells [182]. The Bartha and Norden vaccine strains have deletions in both the gE and gl 
glycoproteins [183,221]. 
Glycoprotein gC (82-98 kDa) binds to heparan sulfate proteoglycan on the cell surface 
and is believed to be the primary mediator of viral adsorption to cells [75,76,113, 144, 165, 
189,246,250,306, 307]. The presence of glycoprotein gC is not essential for viral 
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replication, although gC- mutants replicate to lower titers and are quickly outgrown by wild-
type virus, thus there must be other mechanisms, though less effective, for viral attachment 
[113,189,236,250,286,289]. As stated above gC-/gE- mutants are released less efficiently 
and are less virulent [182,250]. The Bartha strain of PRV has a mutation in the signal 
sequence of the gC gene causing a defect in glycosylation and export [235]. Hemagglutinating 
activiQr has been associated with gC and antibodies against gC have been shown to be 
hemagglutination-inhibiting [303]. 
Glycoprotein gG (95 kDa) is produced and secreted from virus infected cells, but does 
not appear to be part of the virion itself and its function is unknown [19,230]. Deletion of this 
glycoprotein does not affect replication in vitro or in vivo and does not affect virulence [126, 
265]. 
Glycoprotein gB is a complex of two smaller subunits gBb (67-68 kDa) and gBc (55-
58 kDa) which remain linked through disulfide bonds after cleavage of a larger precursor, gBa 
(110-120 kDa) [147,298]. The sequence of PRV gB shares 50% homology at the amino acid 
level with HS V-1 gB making it the most conserved of the glycoproteins among the herpes 
viruses [234]. It is essential for virus replication in cell culture [228]. Glycoprotein gB is 
involved in membrane fusion events such as viral penetration, fusion with outer nuclear 
membrane to release enveloped viral particles into the cytoplasm and cell to cell spread of the 
virus [215,227]. Glycoprotein gB" PRV mutants which were phenotypically complimented 
by replication in a gB expressing cell line, were avirulent for mice [216]. 
Glycoprotein gD (50-60 kDa) is another essential glycoprotein of PRV [220,227]. 
Glycoprotein gD is involved in heparin resistant adsorption and penetration of cells [66,112, 
215,227]. But unlike gB and gH, it does not appear to be necessary for cell to cell spread 
because although progeny virus is noninfectious, phenotypically complemented gD" mutants 
are able to form plaques in cell culture and are able to spread and retain some virulence for mice 
and pigs [93,213,215,216, 227]. Glycoprotein gD" mutants that are complemented by 
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propagation on gD expressing cell lines are being examined as non-transmissible, live PRV 
vaccines [93,181,213,216]. 
Glycoprotein gH (95 kDa) is another structural glycoprotein that is essential for PRV 
replication [132,214]. Like gB, it is required for both penetration of cells as well as cell to cell 
spread of virus [214]. Glycoprotein gL (20 K) probably complexes with gH and is required 
for processing and cell surface expression of gH and, in this respect, is also an essential 
glycoprotein [130]. Functional analysis of gK, gM and gN have not been reported. 
Latency. An important factor in the transmission of many of the herpes viruses, 
including PRV, is their ability to establish lifelong latent infections [23,242,244]. Similar 
situations are seen with other herpes virus infections such as herpes simplex and varicella-
zoster which causes chicken pox. The difference between these diseases and pseudorabies 
when it comes to reactivation of latent virus is that there is a recrudescence of clinical signs, 
cold sores with herpes simplex I and shingles with chicken pox, whereas with pseudorabies 
the reactivation is usually asymptomatic. 
Nervous tissue, especially sensory ganglia, is the most common place for latent PRV to 
reside although other sites, such as tonsil, have been implicated [23, 33, 44, 80, 88,168,240, 
241,264, 296]. During acute infection, the pseudorabies virions can infect nerve endings in 
the oronasal caviar and travel through the axons to nerve cell bodies in sensory ganglia, such as 
the trigeminal ganglia, where the genome can remain until an as yet unknown stimulus causes 
it to reactivate, replicate and be shed back into the environment. The viral genome jqjpears to be 
in a linear nonintegrated state but fails to replicate fully to produce infectious virus [240]. 
Similar to other alphaherpesviruses (eg. HSV-1, HSV-2, VZV, BHV-1), the transcription 
pattern during latency is di£ferent from that of a productive infection. Transcription is limited 
to a few transcripts from a small portion of the genome overlapping the IE 180 gene, but 
transcribed from the opposite strand [40,145,225, 237]. The mechanisms behind the 
establishment, maintenance and reactivation from latency are still unclear. Latent virus can 
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reactivate spontaneously or be induced to reactivate by exogenous stimuli such as ACTH or 
corticosteroid administration [53,58,174,190,279,296]. Thus, the ability of recovered pigs 
to remain as asymptomatic persistent carriers and disseminators of the virus remains a key to 
continued spread of the disease. 
During latency, the virus is largely protected from the immune system because of 
location and lack of viral protein expression to identify infected cells. Prior vaccination or 
passive immunity does not prevent establishment of a latent infection with virulent virus. In 
addition, attenuated vaccine virus strains can establish viral latency themselves [53,174,176, 
190,249,279,280,283,296]. Although vaccine strains have been reactivated from latency 
by administration of corticosteroids, this appears to be a rare event and may be due to a 
decreased ability to establish or reactivate from latency [176,280,283]. There is evidence that 
prior infection and establishment of latency with an attenuated strain of PRV may decrease the 
level of viral latency following subsequent infection with virulent PRV [247]. 
In vitro reactivation of latent virus following tissue explantation [247], in vivo 
reactivation following repeated administration of large doses of corticosteroids [31,53,170, 
174,190, 264, 279, 280, 296], solution and blot hybridization [17, 88, 168], in situ 
hybridization [15, 32,240], and polymerase chain reaction [16, 31, 80,146, 151,264] are 
several methods for detecting latent PRV infections in swine. Reverse transcriptase PGR for 
detection of latency transcripts and quantitative PGR assays have also been developed to study 
PRV latency [43,44, 146,248]. 
Immune response. Both humoral and cell-mediated immunity are believed to be 
important in recovery and protection from PRV infection. It is known that neutralizing 
antibodies provide some protection from disease but they do not prevent infection and 
replication of the virus. Cell-mediated immunity is believed to be important to recovery from 
infection with PRV by destroying virus infected cells and preventing cell-to-cell spread where 
antibodies cannot reach. 
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Neutralizing antibodies to PRV begin to appear 7 to 10 days after infection and reach a 
peak 2 to 4 weeks after infection [89,238,299]. Maximiun antibody titers in sows vaccinated 
with attenuated vaccine peak a few weeks later and titers were generally lower than those of 
sows infected with virulent virus [299]. Greater antibody response to virulent challenge may 
be due to better replication, yielding greater antigenic mass than acheived following infection 
w i t h  a t t e n u a t e d  s t r a i n s  o f  P R V  [ 2 9 9 ] .  I n  P R V  i n f e c t e d  p i g s ,  I g M  a n t i b o d i e s  a p p e a r  fi r s t ,  5 - 7  
days after infection, reach a maximum at day 14, and disappear by day 35 [119,238]. In pigs 
vaccinated intramuscularly with inactivated vaccine, IgM antibodies had disappeared by day 18 
while still elevated in PRV infected animals [238]. IgG antibodies appeared by day 7 after 
infection and day 10 after vaccination, while IgA antibodies were detected by day 10, and in 
infected pigs only [238]. By day 18 IgG, IgM and IgA antibodies were still found in sera and 
oropharyngeal swabs of infected pigs but only IgG was found in samples from vaccinated pigs 
[238]. Secondary antibody responses as a result of challenge after vaccination occurred 
between 3 and 6 days after challenge, 4 to 5 days earlier than the primary response [161]. 
Porcine IgGl, IgG2 and IgM can neutralize PRV and neutralization is enhanced by the 
addition of complement, but IgA has only weak neutralizing capabilities [121]. In one study, 
after administration of virulent virus or attenuated virus intranasally, both IgM and IgA were 
produced in mucosal secretions, while parenteral administration of an inactivated virus induced 
only a weak IgM response mucosaily [121]. In another study, parenteral administration of live 
vaccine induced a better IgA and ADCC response in the nose and trachea than did intranasal 
vaccination. However, intranasally vaccinated pigs were better protected, indicating that 
mucosal IgA levels did not correlate well with protection [160]. 
Antibody responses measured by ELJSA, virus neutralization, ADCC and complement 
mediated lysis are all present after vaccination and challenge but often do not correlate well with 
protection [161]. Thus, it is theorized that cell-mediated immunity may play an important role 
in protection from PRV infection. However, immune serum and some monoclonal antibodies 
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administered to pigs can afford limited protection fiom PRV challenge. While passively 
acquired antibodies ftom the colostrum of sows protects piglets from virulent challenge, it can 
also blocks active vaccination of the piglets [6,299]. Anti-PRV antibody titers persist for long 
periods, probably the lifetime of the animal, and may partially be maintained by increases in 
titer during periods of viral reactivation [175,179,299]. 
Pseudorabies virus replicates in the nucleus of cells and buds through the nuclear 
membrane from which it obtains its envelope. Glycoproteins produced during viral infection 
are found embedded in the nuclear as well as plasma membranes of infected cells. 
Glycoproteins in the plasma membrane can serve as markers to identify infected cells and target 
them for destruction by such immune mechanisms as antibody-dependent cell-mediated 
cytotoxicity (ADCC). Antibody-dependent cell-mediated cytotoxicity activity has been 
demonstrated against pseudorabies virus infected cells using peripheral blood leukocytes and 
cells from pulmonary mucosal washings with polyvalent antiserum to pseudorabies virus [11, 
65,98,116,295]. Of the peripheral blood leukocytes, neutrophils appear to be important in 
mediating ADCC, while in the lung pulmonary macrophages appear to mediate ADCC [65, 
116]. In vitro infection of pulmonary lavage cells led to loss of ADCC activity, whereas it did 
not in peripheral blood leukocytes [65]. The fact that PRV will replicate in macrophages, 
inhibit their function, and eventually lyse them may affect ADCC activity in the lung. When 
antibodies from pigs vaccinated with gB, gC, or gD were used with peripheral blood 
leukocytes, ADCC activity was mainly associated with antibodies to gC [116]. Leukocytes 
fit>m neonatal pigs (4 to 6 days old) appear less capable of mediating ADCC than leukocytes 
from older pigs (greater than 3.5 months old). This may, in part, explain why young pigs are 
more severely affected by the disease [65,116]. 
Unlike vaccinal immunity, immunity induced after natural infection appears to prevent 
reinfection for a period of time. In experiments where reinfection was attempted after recovery 
from an initial challenge, no rise in antibody titer or viral shedding was detected [125]. 
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Additionally, the more replication efficient and virulent the vaccine virus, the better the 
protection appears to be [124,125,126]. Since the administration of immune serum or the 
induction of high levels of virus neutralizing antibodies does not prevent infection, cell-
mediated immune responses are believed to be important in this effect One possibility for this 
period where reinfection does not occur, is the presence of a memory cell-mediated immune 
response. This response may destroy virus infected ceils before production of infectious virus, 
resulting in no restimulation of a humoral immune response [125]. Cell-mediated immunity as 
demonstrated by lymphocyte proliferation in response to whole PRV antigen and cellular 
cytotoxicity against PRV infected cells has been demonstrated [123,160,269, 295]. 
Stimulation of peripheral blood mononuclear cells from PRV immune pigs with PRV antigen 
stimulates predominantly CD4/CD8 double-positive T lymphocytes which may be a population 
of memory/effector T cells in swine [310]. The lymphoproliferative response is stronger when 
animals are exposed to virulent virus versus attenuated vaccine [123]. The lymphoproliferative 
response is also greater with the production of more gamma interferon producing cells when 
attenuated versus killed vaccine was given despite a similar antibody response (Zuckermann 
personal cotmnunication). Exposure to virulent virus produces a secondary B and T cell 
response in vaccinated pigs. Only a secondary T cell response occurs if reinfection with 
virulent PRV occurs within a few months of initial exposure [123]. In PRV challenged pigs, a 
cell-mediated response, as detected by lymphocyte migration inhibition, was seen 4 days after 
infection while VN antibodies were not detected until 7 days after infection [89]. The antigens 
nx)st important in stimulating cell-mediated immunity are still largely unknown. Lymphocytes 
from PRV immune pigs proliferate in response to stimulation with glycoproteins gB, gC, or 
gD, and gC has been implicated as an inducer of cytotoxic T cells [123,309,312]. 
Similarly to PRV, cell-mediated immunity is believed to be important in protection from 
herpes simplex virus infection. In work done with the herpes simplex viruses, there is 
conflicting evidence as to which proteins of the virus are important in inducing cell-mediated 
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immunity. Glycoproteins are thought to be important because lysis of target cells infected with 
tenqierature sensitive mutants defective in glycoprotein production by lymphocytes of HSV 
immune mice was significandy decreased [38]. Likewise, the T cell-mediated lysis of HSV 
infected target cells chemically treated to inhibit glycoprotein synthesis was also decreased 
[143]. In another study however, a significant portion of cytotoxic T cells recognized target 
cells expressing immediate-early proteins of HSV [156]. Cytotoxic T lymphocytes have been 
found in HSV immune mice which lyse target cells expressing the immediate early proteins 
ICP4 and ICP27 but not ICPO [9, 162,204]. The significance of the response to immediate 
early proteins is questionable since mice immunized with a vaccinia virus/ICP4 recombinant 
did not produce cytotoxic T cells and were not protected against lethal infection with HSV 
[162]. Also, although mice vaccinated with ICP27 developed a cytotoxic T cell response, there 
was only partial protection from lethal challenge with HSV [9]. 
Glycoproteins gB, gC and gD have all been shown to be important in the protective 
immune response to HSV. Mice vaccinated with vaccinia virus recombinants expressing these 
glycoproteins were protected from lethal challenge with HSV [37,54,211,288]. There has 
been conflicting evidence as to the character of the immune response to these glycoproteins. 
Most evidence supports the claim that gB induces a cytotoxic T cell response. Lymphocytes 
from mice vaccinated with a vaccinia virus expressing gB, a gB peptide epitope or gB 
expressing cell line, and T cell clones derived by stimulation of anti-HS V lymphocytes with gB 
are all capable of lysing HSV infected target cells [24,28,171,304]. Also, cells from HSV 
immunized mice of some haplotypes are able to lyse gB expressing target cells and different 
haplotypes recognize different peptide epitopes of gB [24,91,205,291]. This may explain 
the reason that vaccinia viruses expressing gB or gD induced a neutralizing antibody response 
and CD4'^  T lymphocytes but not QD8'^  cells and no cytotoxic T cell response in various 
strains of mice. They provided only partial protection and were unable to rapidly eliminate 
epithelial infection [155]. 
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There is a fair amount of evidence, including the above mentioned study, which 
indicates that gD stimulates a T helper response and neutralizing antibody response but not a 
cytotoxic T cell response [24,157,158,239,300]. Some studies have indicated that anti-
HSV T cell clones are able to lyse gD expressing target cells and CDS"'" T cell clones generated 
by stimulation of anti-HSV lymphocytes with gD are able to lyse HS V infected target cells 
[109, 304]. 
Only a few studies examining cell-mediated immunity associated with gC have been 
performed. One study demonstrated that cytotoxic T lymphocytes from HS V immunized mice 
were able to lyse gC expressing target cells, but work done by the same group of investigators 
at a later date found that a different clone of the gC expressing cell line was not lysed [239, 
291]. Another smdy demonstrated that anti-HSV cytotoxic T cell activity directed against target 
cells infected with a mutant unable to express gC was decreased and concluded that gC was a 
major cytotoxic T cell antigen [85]. Some of the conflicting reports may have to do with the 
fact that the work with HS V is done with inbred mice and different haplotypes of mice may 
react in different ways to antigens based on their MHC expression. 
Delayed type hypersensitivity responses can be induced in PRV immune pigs by 
intradermally injecting heat inactivated PRV [253,260]. Non-specific immune mechanisms 
mediated by natural killer cells and interferon production may be important in recovery from 
initial infections with PRV. Natural killer cell activity has been demonstrated using peripheral 
blood leukocytes and cells infected with PRV or expressing glycoproteins gB or gC [122, 
159]. Interferon alpha has been shown to protect fibroblastic cells from viral infection or 
reduce virus replication in epithelial cells in vitro [224]. 
Immune response to glycoproteins. Not only do glycoproteins perform 
in^wrtant functions for the virus, they are also prominent antigens to which the host responds. 
Antibodies to glycoproteins are prominent in convalescent sera of swine [223,266]. 
Preparations of glycoproteins administered to mice and pigs were able to afford some 
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protection from virulent challenge but did not induce DTH responses after subsequent injection 
with inactivated PRV, whereas there was a DTH response when mice were vaccinated with 
inactivated virus [226]. Envelope andgens delivered through immunostimulating complexes 
induced neutralizing antibody and lymphoproliferative responses and protected mice against 
lethal challenge [270]. Glycoproteins gB, gC and gD appear to be important in stimulating 
protective humoral and, possibly, cell-mediated immuni^. 
Monoclonal antibodies to gB and polyclonal antisera to gB have neutralizing activity 
against PRV but often the presence of complement is needed to see this effect [98,163,164, 
196,197,268,301]. Monoclonal antibodies given passively to pigs, purified preparations of 
gB given to mice or pigs, and recombinant gB produced by a baculovirus expression system 
given to mice, all have induced at least partial protection from virulent PRV challenge [152, 
163,164,197,301]. Glycoprotein gB delivered through immunostimulating complexes was 
able to protect mice and pigs from lethal infection [268]. When gB, gC or gD were delivered 
through a vaccinia virus vector, alone or in combination, all were able to protect mice and pigs 
with protection being greatest with the gB/gC combination in mice and the gB/gD combination 
in pigs [233]. Lymphocytes from PRV immune pigs proliferate in response to gB [123]. 
Antigenic variation among PRV isolates has been found, especially between different 
geographic areas, but conflicting results have been reported with regard to antigenic variation 
of gB. Where one group has demonstrated antigenic variation of gB by neutralizing 
monoclonal antibodies [302] another group detected no drift in gB [18]. 
A large portion of the neutralizing activi^ of convalescent swine sera is directed against 
gC [18]. Monoclonal antibodies to gC and polyclonal antibodies raised to gC neutralize virus 
independent of the addition of complement [90,98, 103,163,164]. Monoclonal antibodies to 
gC given passively to mice and pigs, and gC delivered through a vaccinia virus vector to mice 
and pigs, protected from virulent challenge [67, 152]. When gB, gC, gD or all three were 
given to mice, those mice given gB, gC, or the mixture of all three were protected as compared 
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to controls. A high dose of gC and both high and low doses of the mixture of all three 
protected best In this study protection did not conelate well with neutralizing antibody 
response [164]. Antibody-dependent cell-mediated cytotoxic activity has also been reported 
using sera from pigs vaccinated with gC or modified live virus but there was only a minimal 
response firom the sera of pigs vaccinated with gB or gD [98]. Lymphocytes firom PRV 
immune pigs proliferate in response to stimulation with gC and it has been implicated as an 
inducer of cytotoxic T cells [123, 309,312]. Both groups that looked at antigenic variation of 
PRV found drift associated with glycoprotein gC [18,302]. 
Glycoprotein gD appears to be one of the most potent inducers of virus neutralizing 
antibodies. Antibodies to gD are also capable of neutralizing the virus independent of the 
addition of complement although the titer is sometimes increased when complement is added 
[98,164]. Out of 108 monoclonal antibodies generated in one study, 12 were able to 
neutralize virus and all of these were specific for gD [67]. Monoclonal antibodies to gD given 
passively to mice or swine are also able to protect &om virulent challenge and mice immunized 
with antiidiotypic antibody to a monoclonal antibody of gD were protected from lethal infection 
[67,152,267]. Glycoprotein gD given as subunit vaccine was able to protect mice and pigs. 
When gD was given to pregnant sows, they transmitted VN antibodies through their colostrum 
to their piglets and the piglets were protected [106,154,192]. Pigs vaccinated with viral 
recombinants expressing gD, including a vaccinia virus recombinant, a swinepox virus 
recombinant (which also expressed gl), and a non-replicating adenovirus recombinant 
combined with an adjuvant, were protected from challenge and had reduced shedding of 
virulent virus [1,68,81,233,274]. Lymphocytes from PRV immune pigs proliferate in 
response to stimulation with gD [309]. 
Litde virus neutralizing activity appears to be associated with gE in the convalescent 
serum of swine [18]. Monoclonal antibodies to gE failed to neutralize virus even with the 
addition of complement in one study [90]. However, another study demonstrated monoclonal 
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andbcxiies to an immunodominant domain of gE, as well as antibodies raised by vaccination of 
mice with a fusion protein containing this domain, had complement dependent neutralizing 
activity and were protective for mice [77]. Antigenic variation was detected in gE [18]. 
Antibodies to other proteins of PRV like the IE protein are detected in naturally and 
experimentally infected swine but antibodies raised to this protein have no neutralizing activity 
[42]. 
Vaccines and differential testing. There is another aspect to antibody formation 
against the glycoproteins that is important Differential testing, which is important to the 
eradication program, utilizes tests which can detect antibodies to specific glycoproteins. These 
tests can differentiate between animals that have an immune response as a result of vaccination 
as opposed to those that have been naturally infected with PRV. The vaccines have deletions in 
genes that code for certain glycoproteins. Vaccinated pigs should have no antibody to the 
deleted glycoprotein whereas pigs infected with wild-type vims will have antibodies which can 
be detected by an ELISA test The effectiveness of a deletion-mutant vaccine depends on 
selection of a protein that is sufficientiy immunogenic to induce a detectable and persistent level 
of antibody even in vaccinated pigs naturally exposed to minimum dose of virulent virus. The 
most common nonessential genes that have been deleted ficom these vaccines are the genes 
encoding gC, gE and gG but most countries are now predominantiy recommending gE deleted 
vaccines as part of their eradication programs. Most differential tests appear sensitive but in a 
study where sows were vaccinated with a gE negative vaccine, piglets which received maternal 
antibodies fix>m these sows and were subsequently challenged with a low dose of virulent PRV 
had inconsistent seroconversion to gE [277]. 
Gene-deleted modified-live, killed and subunit vaccines that have companion differential 
tests are on the market Vaccination for pseudorabies is common, and in general, both 
attenuated and inactivated vaccines prevent or reduce morbidity and mortality, decrease the 
amount of virus shed after infection or during reactivation, and increase the threshold for initial 
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viral infection to take place [293]. Theiefoce, current vaccines can play a role in decreasing 
dissemination of the disease. Unfortunately, no vaccine has been able to totally prevent 
infection and replication of the virus or the establishment of latent infections. In fact, a vaccine 
virus has been shown to establish and reactivate from latency [176]. 
It is important to determine which vaccines induce the best balance of both humoral and 
cellular irmnunity. Killed or subunit vaccines typically induce a better humoral response than 
they do cell-mediated response, at least in the context of cytotoxic T lymphocytes. Killed virus 
does come into contaa with B lymphocytes and can also be phagocytized by antigen presenting 
cells so that humoral immunity is stimulated. Adjuvants incorporated into vaccines can 
influence the degree to which different arms of the immune system are stimulated. Because 
higher antibody levels are often induced by killed vaccines, they also tend to contribute to 
higher passively acquired colostral antibody titers[178,293]. This can be of benefit in 
protecting neonatal pigs but also a disadvantage when trying to stimulate an active immune 
response through vaccination of young animals. Thus far, attempts to vaccinate piglets that 
have maternally derived antibody titers has not been very successful [6,7,47, 61, 63,118, 
127,142, 166,275,276,278,281,295]. Only when maternally derived antibody levels are 
low is active immunity induced. There is some evidence that administering attenuated vaccines 
intranasally may stimulate active immunity in pigs with matemally derived antibody. [7,61, 
166, 275, 276, 278, 281] 
Live attenuated vaccines tend to have a better balance of stimulating both humoral and 
cell-mediated immunity, and thus in many instances tend to induce better protective immunity. 
This appears to be the case with pseudorabies vaccines as well. When an attenuated vaccine 
was given to pigs their PBMC responded with a greater proliferative response and produced 
more gamma-interferon producing cells than PBMC ftom pigs vaccinated with an inactivated 
form of the same vaccine (Zuckermann personal communication). The fact that attenuated 
pseudorabies vaccines are unable to prevent viral replication and the establishment of latent 
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infections may be due to a decrease in replication or dissemination of the vaccine virus in the 
animal. These viruses can themselves become latent but they appear not to be reactivated as 
readily fiiom a latent state. Whether this is due to a decreased abiliQr to establish, maintain, or 
reactivate fiom latency is unknown. There is some evidence that an attenuated viral strain may 
be able to establish a preemptive latent infection where there is decreased establishment of 
latency by a subsequent virulent virus infection. Some disadvantages of live vaccines, 
although rare, are the potential to cause disease by reversion to virulence and the potential for 
recombination with wild-type virus or a different attenuated vaccine virus [48,57, 84,94,95, 
114,115]. The latter not only has the potential to cause the vaccine virus to revert to a virulent 
strain, it could also result in the loss of the ability to differentiate infected &om vaccinated pigs. 
The route of vaccine administration can be important, as well, in inducing the best 
protective response. As compared to the intramuscular route, modified-live vaccines 
administered intranasally can reduce viral shedding to a greater extent after acute infection and 
during reactivation of latent infection [61, 62, 166, 178,217, 275,276, 278, 280, 281]. This 
may be due to stimulation of local mucosal inmiime responses and in the case of reactivation 
from latency, due to the development of a preemptive latent infection with the vaccine. 
Vaccinia virus based vectors. Vaccinia virus was used as a vaccine in the 
eradication program for smallpox. The origins of vaccinia virus are unknown but it may have 
evolved from variola virus or cow pox virus through repeated passage [35]. Small pox was 
eradicated largely because of the properties of vaccinia as a vaccine, namely its stability, low 
production cost, ease of administration and long lasting immunity [14]. With the advent of 
genetic engineering techniques, the idea of using vaccinia as a vector to express foreign genetic 
material and as a vaccine became feasible. There is still some concern regarding the use of 
vaccinia virus based vectors as vaccines. This is largely associated with the broad host range 
of the virus and rare but serious side effects the virus can cause in immunocompromised people 
[111, 195]. 
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Vaccinia virus belongs to the family Poxviridae subfamily Chordopoxvirinae 
(poxviruses of vertebrates) which are large (250 by 350 nm) double stranded DNA viruses that 
replicate in the cytoplasm of infected cells [72,191]. The genome, which is about 190 kbp in 
size, is linear, AT rich and has inverted terminal repeats containing direct tandem repeats and 
hairpin loops at both ends [82,83, 86, 87,292]. Viral gene expression is under temporal 
control and gene products are assigned to either early, intermediate, or late classes based on 
requirements for protein or DNA synthesis [191,263]. Because of its site of replication, the 
virus must encode its own transcriptional and DNA replicative machinery. The virion is made 
up of more than 1(X) polypeptides and consists of a core, lateral bodies, membrane and the 
extracellular form has an envelope [35]. Many techniques for the introduction of foreign 
genetic material into nonessential regions of vaccinia virus have been described and all rely on 
homologous recombination of transfected DNA with infectious virus. Extensive reviews on 
the construction of poxviruses recombinants have been written [148, 149,263]. 
Many foreign genes have been successfully expressed by recombinant vaccinia viruses 
and most undergo appropriate post translational modification [37,54, 117,133,150,153, 
157, 158,162,171,211,258,288, 304]. Studies using vaccinia vectored vaccines have 
protected animals fix>m disease [30, 37, 54, 133, 150,153, 211, 258, 288, 290]. Stimulation 
of both cell-mediated and humoral immune responses to foreign antigens expressed by vaccinia 
virus recombinants has been demonstrated which is important for protective immunity against 
many pathogenic organisms [22, 30, 37, 54, 133, 150, 154, 157, 158, 162, 171, 211, 288, 
290,304]. Selection of a vaccinia virus promoter to control expression of a foreign gene may 
be important in the type of immune response that is induced. The choice of promoters 
influences the level of gene expression and when during the viral replicative cycle the protein is 
expressed. Studies have found that some proteins under the control of an early vaccinia virus 
promoter were able to induce cytotoxic T cell responses while the same proteins expressed 
under the control of a late viral promoters did not [52,284]. The cause of this may be due to 
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the lack of adequate MHCI expression late in viral infection caused by the inhibition of host 
protein synthesis or inhibition of proteolysis and processing of antigens [5]. 
Vaccinia virus encodes other proteins which may modulate the hosts immune system 
[4,254,255]. Vaccinia encodes three proteins that have homology to the serpins, or serine 
protease inhibitors (ORFS K2L, B13R, C12L Copenhagen strain) [29, 137,257]. Smdy of 
these vaccinia encoded proteins shows they inhibit inflammatory responses by inhibiting 
diHETE synthesis, a neutrophil chemoattractant, and the production of IL-lb by inhibiting the 
EL-lb converting enzyme [210,229]. Vaccinia can also decrease inflammatory responses by 
expression of a steroid synthesizing enzyme (ORF A44L Copenhagen strain) [25, 87,256]. 
These viruses also produce proteins which block the intracellular actions of interferons and 
bind complement control factors (ORFS K3L, E3L, C3L, B5R Copenhagen strain) [2,13, 39, 
59, 60, 104,105,135,207, 208, 231, 232, 287]. Vaccinia strains also contain open reading 
firames with homology to cytokine receptors, specifically IL-1, TNF, and IFN-g receptors, 
which can bind and interfere with the functions of these cytokines (ORFS B16R, C22L, 
B28R, B8R Copenhagen strain) [3, 87, 96, 172, 259, 261, 271, 272]. 
The genome of vaccinia virus is large and although the genes are densely packed with 
little intervening genetic material nearly one-third of the genome is dispensable for replication in 
cultured cells. Because of this and the flexibility in packaging its DNA, it is possible to create 
multivalent vaccines. Vaccinia vectored vaccines have been created that express two or three 
foreign proteins and immune responses to each of the recombinant proteins was demonstrated 
[74, 219]. 
There is conflicting evidence as to whether prior exposure to vaccinia virus or the 
expressed antigen by its natural route will inhibit optimal responses to a vaccinia vectored 
vaccine. In some studies, prior exposure to vaccinia or expressed antigen has reduced the 
magnitude of the immune response and in others it has not [108,141]. These conflicting 
results are probably a result of choice of antigen, vaccination protocol, and particular vaccinia 
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recombinant used. Thus, the vaccinia strain used, choice of promoters and genetic engineering 
techniques, choice of immunogen to be expressed, and determination of levels of protective 
immuniQr through challenge studies are all variables which must be examined to optimize the 
specific vaccine. 
An ideal live recombinant vaccine is nonpathogenic but able to elicit a strong protective 
immune response. A major concern for the use of vaccinia vectored vaccines is the rare 
occurrence of severe complications when vaccinia was used in the small pox eradication 
program [14, 111, 195]. Progress has been made in identifying virulence factors and host 
range genes of vaccinia which can be deleted to make the virus safer. The NYVAC strain of 
vaccinia virus was derived from the Copenhagen strain of vaccinia virus after its genome had 
been completely sequenced and some of the genes encoding virulence and host range functions 
were identified [13, 34, 36, 45, 86, 87, 134, 135, 136, 212, 218, 251, 305]. A total of 18 
open-reading frames were deleted resulting in decreased virulence and debilitated replicative 
capacity in cells derived from mice, swine, equids and humans while maintaining its ability to 
replicate efBcientiy in chick embryo fibroblasts [262]. Among the open reading frames deleted 
from NYVAC are two genes involved in nucleotide metabolism, the thymidine kinase (J2R) 
and the large subunit of the ribonucleotide reductase (14L); the gene encoding the viral 
hemagglutinin (A56R); the remnant of the gene responsible for the formation of A-type 
inclusion bodies (A26L); the disrupted gene encoding a serine protease inhibitor (B13R/B14R); 
and a block of 12 open reading frames including two known viral host range regulatory 
functions (C7L, KIL) and secretory proteins involved in neurovirulence G^IL) and one which 
has homology to the complement 4b binding protein (C3L) [262]. It has been postulated that 
the intact functions of these proteins is to enhance the ability of the virus to replicate in 
quiescent cells, interfere with complement mediated lysis of infeaed cells, and prevent the 
chemotactic signaling of neutrophils or otherwise subvert host defense mechanisms against 
viral infections. Besides these deletions, the genes for the TNF receptor and EL-l receptor 
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homologues of the Copenhagen strain of vaccinia virus are disrupted by frameshift mutations 
[3, 87. 271]. 
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Abstract 
Poxvirus recombinants, based on the highly attenuated NYVAC strain of vaccinia virus 
(Tartaglia stflL 1992), containing single gene inserts encoding the pseudorabies virus (PRV) 
gll, gin, or gp50 glycoproteins were tested for their immunogenicity in pigs. Twenty-four 
pigs were randomly divided into six groups of four. Groups 1-3 were inoculated with 10^ 
CCID50 of NYVAC/PRV gn, NYVAC/PRV gUI, or NYVAC/PRV gp50, respectively, while 
groups 4 and 5 received the NYVAC parent virus or an inactivated PRV vaccine control, 
respectively. Group 6 represented the sham vaccinated control group. All inoculations were 
given by the intramuscular route on weeks 0 and 4. The candidate vaccines were shown to be 
safe with no local or systemic reactions. At 4 weeks following the second inoculation, all pigs 
were challenged by an oronasal administration of a virulent PRV strain. Pigs were monitored 
before and after challenge for clinical manifestations resulting &om vaccination and challenge 
exposure, respectively. Sera were analyzed for PRV neutralizing activity. Virological analyses 
after challenge included assessment of virus shedding and the development of latent PRV 
infections. All but one animal developed latent PRV infection following challenge exposure; 
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however, significant protection against PRV-induced signs was afforded by vaccination with 
either the NYVAC/PRV gp50 or NYVAC/PRV gH recombinant viruses, as well as with the 
inactivated PRV vaccine. The NYVACyPRV gp50 also reduced overall virus shedding after 
challenge. The extent of protection against PRV-induced clinical signs, in general, was 
associated with the level of pre-challenge virus neutralizing activity. 
Introduction 
Pseudorabies (PR) is a major problem in the pork industry in the United States and 
many other countries, to the extent tliat eradication programs now exist (Thawley and 
Morrison, 1988). PR can be fatal in young piglets and, although the disease can be mild to 
asymptomatic in older animals, it can cause reproductive failure in pregnant gilts or sows 
(Gustafson, 1986). The disease is caused by an alphaherpes virus which establishes latent 
infection in several tissues, most consistentiy the trigeminal ganglia and, less frequently, the 
brain and tonsils (Sabo, 1985; Brown si sL 1990). Recrudescent infections result in the 
shedding of virus into the environment compounding the problem of eradicating the disease 
(Schoenbaumsial., 1990). 
There is some debate on the role of vaccines in pseudorabies virus (PRV) eradication 
programs. To date, no vaccine has been able to prevent viral infection or the establishment of 
latent infection (Wittmann, 1991). Certain vaccines, however, successfiiUy lessen clinical 
signs of PR disease and slow its spread. To date, PRV vaccine candidates have consisted of 
attenuated or inactivated PRV strains. The present trend is to use gene-deleted PRV vaccine 
strains that enable differential testing of vaccinated versus infected swine (van Oirschot £i M-, 
1990). Although attenuated vaccine strains have been regarded as the most potent at 
stimulating a clinically protective immune response, some concern exists regarding their ability 
to recombine with wildtype virus resulting in reversion to virulence or the inability to 
distinguish vaccinated from infected animals (Henderson si al-, 1990; Mengeling, 1991; Volz 
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fiial.. 1992). Using inactivated PRV vaccine preparations is a concern since there is a 
possibility of incomplete inactivation. Further, inactivated vaccines have not been as effective 
as attenuated vaccines in inducing a protective immune response even though they often elicit 
greater levels of neutralizing antibodies (Wittmann, 1991; Mengeling £ial-. 1992). 
The use of vector-based vaccine candidates, including vaccinia virus, have some 
intriguing advantages and provide alternative strategies for overcoming at least some of the 
shortcomings of conventional vaccine types (Tartaglia and Paoletti, 1990). Vector-based 
candidates eliminate the use of the disease-causing virus in immunizing the animal by 
incorporating only relevant immunogens. Such vaccines also enable the development of 
diagnostic tests for distinguishing vaccinated from infected swine. 
Vaccinia virus-based PRV recombinant viruses have been shown previously to protect 
pigs against a PRV challenge exposure (Riviere £t al., 1992). Despite these and other 
encouraging results, safety issues have delayed further development of such vaccine products. 
Recendy, a novel vaccinia virus strain was developed with highly attenuated characteristics 
compared to existing vaccinia virus vaccine strains. NYVAC was the designation given to this 
highly attenuated vaccinia virus vector derived by genetically engineering the deletion of 
putative virulence and host range genes from the Copenhagen vaccinia virus vaccine strain 
(Tartaglia sj al., 1992). NYVAC has debilitated growth properties in cells derived from a 
number of species, including swine, but retains full replicative capacity in accepted cell 
substrates for vaccine production such as primary chick embryo fibroblasts (Tartaglia si al-. 
1992 and unpublished observations). Significandy, the highly attenuated NYVAC vector 
retains excellent immunizing capacity. 
The present smdy was designed to evaluate the highly attenuated NYVAC strain 
expressing PRV glycoprotein genes gll, gin, or gp50 (herpes simplex virus homologues gB, 
gC, and gD respectively) for safety and immunogenicity in swine. 
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Materials and Methods 
Cells and virus 
Identification, cloning, and nucleotide sequence analysis of the PRV gll, gin, and 
gp50 genes from the NIA3 strain were described previously (Riviere 1992). NYVAC 
(vP866), a highly attenuated vaccinia virus strain, was derived from the Copenhagen vaccine 
strain by serial deletion of virulence-associated and host-range genes (Tartaglia st al*. 1992). 
NYVAC-based PRV recombinant viruses containing either the gll, glU, or gp50 genes were 
generated by standard procedures using insertion plasmids pPR18 (Riviere si al-, 1992), 
pPRVnrVCTK, and pATIgpSO, respectively. Insertion plasmid pPRVDIVCTK was derived 
by insertion of a 1.5 kb SnaBl/Dra I fragment from pPR24 (Riviere fiial-. 1992) into pSD513 
(Tartaglia £i al-. 1992). Insertion plasmid pATIgp50 was constructed by initially excising a 
1.3 kb Nsi V partial BgL H fragment from pPR29 (Riviere si ai., 1992) and positioning this 
fragment downstream from a 126 bp vaccinia sequence containing the I3L promoter sequences 
(Goebel fital-. 1990a,b; Vos and Stunnenberg, 1988). This resulted in pBSPRV50I3 which 
provided the source of the gp50 expression cassette (1.4 kb). The cassette was inserted into 
pSD541 generating pATIgpSO. Plasmid pSD541 was derived as follows. Flanking arms for 
the ATI region (ORF A26L) (Goebel si al-. 1990a,b) were generated by P(3l using subclones 
of the Copenhagen HindHI A region as template. Oligonucleotides MPSYN267 (5'-GGGCT 
GAAGCTTGCGGCCGCTCATrAGACAAGCGAATGAGGGAC-3') and MPS YN268 
(S'-AGATCrCCCGGGCrCGAGTAATTAATrAATTnTATrACACCAGAAAGACGGCr 
TGAGATC-3') were used to derive the 420 bp vaccinia arm to the right of the ATI deletion. 
Synthetic oUgonucleotides MPSYN269 (S'-TAATTACrGAGCCCGGGAGATATAATITAA 
TITAATITATATAACTCATTmTCCCC-3') and MPSYN270 (S'-TATCTCGAATTCCCG 
CGGUl'l 1AAATGGACGGAACi LTi l l l CCC-3') were used to derive the 420 bp vaccinia 
arm to the left of the deletion. The left and right arms were fused together by PCR and are 
separated by a polylinker region specifying restriction sites for BglU. Smal. and Xhol. The 
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PCR-generated fragment was digested with Hindin and EcqRI to yield sticky ends, and ligated 
into pUC8 digested with Hindin and EcoRI to generate pSDS41. 
The resultant NYVAC-based recombinant viruses containing the PRV gll, gin, or 
gp50 genes were designated NYVAC/PRV gll (vP881), NYVAC/PRV glE (vP883), and 
NYVAC/PRV gp50 (vP9(X)), respectively. In short, vP881 contains the PRV gH gene under 
the control of the vaccinia virus H6 early/late promoter (Goebel £i M-. 1990a,b) at the ORF 
A56R (Goebel fiial.. 1990a,b) insertion locus ; vP883 contains the early B13R (Goebel fit al., 
1990a,b) regulated PRV gin gene at the ORF J2R (Goebel £i al., 1990a,b) insertion locus; and 
vP9(X) contains the PRV gp50 gene under the control of the I3L earlyAntermediate promoter 
(Goebel etal., 1990a,b; Vos and Stunnenberg, 1988) at the ORF A26L (Goebel £tal-, 
1990a,b; Tartagliagial-. 1992) insertion locus. Insertion of the PRV genes was accomplished 
by replacing the endogenous ORFs (J2R, A56R, and A26L) in a manner which prevented the 
synthesis of undesirable novel gene products. Immunoprecipitation and immunofluorescence 
analyses with monoclonal antibodies specific for gn, gin, and gpSO were performed and 
demonstrated proteins of apparent molecular weights similar to those observed in PRV infected 
cells (data not shown). 
An established porcine kidney cell line, PK-15, was used to propagate and titrate PRV 
challenge virus (Indiana-Funkhauser strain) and also to determine PRV virus neutralizing (VN) 
activity. Bovine embryonic spleen (BESp) cells (Mengeling and Van der Maaten, 1988) were 
used for virus isolation from pharyngeal and nasal swabs and to titrate NYVAC viruses. PRV 
titrations were performed by plaque assay (Mengeling, 1991). NYVAC-based viruses were 
assayed using 50% cell culture infectious dose (CCID5Q) as described below. Approximately 
5000 BESp cells in 100 pi of Eagle's minimal essential media (EMEM) supplemented with 
10% fetal bovine serum (FBS) were used to seed each well of a 96 well microtiter plate. Fifty-
|il of serial ten-fold virus dilutions in serum-free EMEM were placed into each of eight wells. 
33 
The infected cells were incubated at 37°C with 5% CX)2 until a final reading 2 weeks post­
infection and the 50% endpoint was calculated. 
Vaccination of pigs 
Twenty-four mixed breed, mixed sex, 4-5 week old pigs were purchased from a PR-
&ee herd and randomly allocated into six equal-sized experimental groups. Each group was 
housed in a separate isolation room during the first part of the study and allowed to acclimate 
for two weeks before initiation of the protocol. Group 1 received the NYVAC recombinant 
containing the PRV gll gene (NYVAC/PRV gll); group 2 received the NYVAC recombinant 
containing the PRV glll gene (NYVAC/PRV gUI); group 3 received the NYVAC recombinant 
containing the PRV gp50 gene (NYVAC/PRV gp50); group 4 received the NYVAC parent 
virus; group 5 received an inactivated PRV vaccine strain; group 6 was the control group and 
received sham injections containing EMEM supplemented with FBS. All pigs received two 1 
ml inoculations via the intramuscular route in the right caudal thigh on weeks 0 and 4. The 
pigs which received the NYVAC-based viruses were inoculated with 10^ CCID50. The 
inactivated PRV vaccine was a commercially derived thymidine kinase-negative and g^C" 
vaccine inactivated with 0.3% acetylethyleneimine. The inactivated preparation was prepared 
in our laboratory and was adjuvanted with 10% aluminum hydroxide prior to inoculation 
(Mengeling ££ al-» 1992). The PRV titer prior to inactivation was 7.4 x 10^ plaque forming 
units (pfiiVml. 
All pigs were monitored for body temperature and clinical signs for 11 days following 
each inoculation. Body weights were measured at weekly intervals. Antibody titers to PRV 
were determined by virus neutralization (VN) at 1,2, and 4 weeks following each inoculation. 
Three weeks after the second inoculation, pigs were regrouped into four rooms, with one pig 
fi-om each group placed in each of the rooms. 
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Four weeks following the second inoculation (week 8), all pigs were challenged with 
10^ pfu of virulent Indiana-Funkhauser (IND-F) strain of PRV via the oronasal route. Body 
temperatures were monitored from 3 days before challenge through 11 days after challenge. 
All pigs were weighed twice weekly from 14 days before challenge through 21 days after 
challenge. Nasal and pharyngeal swabs were taken for virus isolation every other day from 
day 0 through day 11 relative to the challenge and at 14,21, and 28 days after challenge. VN 
titers were determined from serum samples taken at 4 weeks post-challenge. Clinical signs 
were monitored throughout the experiment. The pigs were euthanized and necropsied 4 
months after challenge and trigeminal ganglia were recovered to check for latent infection using 
the polymerase chain reaction (PGR). 
Virus neutralization (VN) titrations 
VN titrations in the absence of complement were performed as previously described 
(Mengeling, 1991). VN titrations in the presence of complement were performed by adding 
complement in the form of rabbit serum to the virus dilution to achieve a final concentration of 
rabbit serum of 10% per well. All results for VN titers provided in Tables 1 and 2 were 
derived from a single assay. 
Virus isolation from nasal and pharyngeal swabs 
Sterile wooden-shaft, cotton-tipped swabs were used to swab the nasal and pharyngeal 
cavities of each pig. The swabs were then submerged in sterile tubes containing 2 ml of 
transport medium (EMEM containing 75 u/ml penicillin, 75 ng/ml streptomycin, 75 ixgAnl 
neomycin, 0.75 u/ml bacitracin, 200 ixgAnl gentamicin, and 5 ^ig/ml amphotericin B). The 
tubes were kept on ice until processed, at which time they were agitated and then centrifuged at 
200 X g for 10 minutes. Two-hundred pi of the supernatant was then inoculated on to a BESp 
cell monolayer in one well of a 24 well plate in which the growth medium had been replaced 
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with inoculation medium (EMEM containing 25 u/ml penicillin, 25 p-g/ml streptomycin, 25 
^ml neomycin, 0.25 u/ml bacitracin, 500 |X^ml gentamicin, and 2 ^g/ml amphotericin B). 
The inoculated plates were kept at 37° C in a moist atmosphere of 5% CO2 and observed for 
one week to monitor for cytopathic effect (CPE). At 24 hrs the number of plaques was 
enumerated and recorded as 1+ for 1-10 plaques, 2+ for 11-1(X) plaques, 3+ for >1(X) plaques 
but less than 100% CPE, and 4+ if 1(X)% CPE was observed (complete CPE was estimated to 
represent approximately 1(XX) plaques). If CPE was not observed until after the initial 24 hr 
observation period, it was recorded as (+). 
Radioimmunoprecipitation (RIP) 
RIP was performed with 35s-methionine-labeled PRV-infected cell lysate and serum 
samples as described previously (Mengeling and Pirtie, 1990; Mengeling st al-, 1988). 
PGR analysis for latent infection of trigeminal ganglia 
PCR was performed on 10% tissue digests of trigeminal ganglia from all pigs. A 
nested set of primers was used to amplify a region within the essential PRV gll glycoprotein 
gene. The outer set of primers ampliiSed a 334 bp fragment while the inner set amplified a 195 
bp segment PCR was performed using conditions described previously (Mengeling stal-. 
1992; Volzfital., 1992; BelakstalM 1989). 
Results 
Evaluation of vaccinated pigs prior to challenge 
No local or systemic reactions were observed following two inoculations of the 
NYVAC parent virus or the NYVAC-based PRV recombinant viruses. As shown in figure 1 
(a and b), pigs in all groups receiving the NYVAC viruses had normal temperature and body-
weight profiles. As expected, no PRV VN activity was detected prechallenge in serum from 
Fig. 1. Mean percent body weiglit gains (a), and mean body temperatures (b), after 
vaccination on days 0 and 28 (weefe 0 and 4). 
37 
200 
ISO-
-Q- NYVAOPRVgn 
NYVAC/PRVgm 
NYVAC/PRVgpSO 
paentNYVAC 
inaaPRV 
oonotoi 
% IQO 
SO 
2iidinj 
Istinj 
—p-
2S 
—P-
35 
—P" 
49 
-P-
14 21 42 56 
42-1 
41-
NYVAC/PRVgH 
NYVAC/PRVgin 
NYVAC/PRVgpSO 
parent NYV AC 
inacLPRV 
control 
I ' I • I 
2S 30 32 34 36 38 40 
1st injection 2nd injection 
Day 
38 
control pigs or pigs vaccinated with the NYVAC parent virus (Table 1). 
Only one pig receiving the recombinant vaccines (pig 12 from the NYVACVPRV gp50 
group) had any detectable VN activity after the first injection (titer of 2 at 4 weeks post-
inoculation). However, all 4 pigs receiving a single administration of the inactivated PRV 
vaccine demonstrated low to moderate PRV VN titers (range of 2-64) 2 to 4 weeks post-
inoculation. Significant increases in VN activity were observed in pigs following a second 
inoculation with NYVACyPRV gll, NYVAC/PRV gin, NYVAC/PRV gp50, or the inactivated 
PRV vaccine preparation (Table 1). Peak VN titers were detected 1 week following the second 
inoculation and declined 2 to 4-fold by 4 weeks. Among the three groups receiving 
recombinant viruses, that receiving the gp50 recombinant demonstrated the highest levels of 
VN activity (512-2048 at 1 week after 2"^ inoculation), comparable to those observed in pigs 
receiving the inactivated PRV vaccine. Animals that received the gll recombinant or the gin 
recombinant had lower VN titers (Table 1), ranging from 8 to 32 and <2 to 16, respectively, at 
1 week following the second inoculatioru No difference in VN activity was observed in any of 
the groups when complement was included in the assay (data not shown). 
Serum samples taken from the recombinant vaccinated groups after the second 
inoculation had the ability to specifically precipitate the cognate PRV glycoprotein by RIP 
(Figure 2). These results illustrate proper expression of the intended PRV glycoprotein in vivo 
by the recombinant viruses. 
Evaluation of pigs following PRV challenge 
Following challenge with virulent PRV, all pigs developed mild to severe signs of PR. 
Subjectively, the control group was affected most severely with 3 of 4 pigs showing 
neurologic involvement, whereas no other pig demonstrated neurologic disorders. Disease 
signs in the group receiving the NYVAC parent virus were less severe and recovety periods 
were similar to those in groups receiving the NYVAC/PRV recombinant viruses or ±e 
inactivated PRV vaccine preparation. The clinical course was similar in the glU recombinant 
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Table 1. Virus neutralization titers in sera collected before vaccination, and at intervals after 
vaccination and challenge. 
Wedc 
Group Pig oi 1 2 42 5 6 
o
o
 
12 
1 <2 <2 <2 <2 8 8 4 2048 
NYVAa 2 <2 <2 <2 <2 8 8 2 2048 
PRVgn 3 <2 <2 <2 <2 16 8 8 2048 
4 <2 <2 <2 <2 32 16 16 512 
5 <2 <2 <2 <2 16 2 <2 1024 
NYVAC/ 6 <2 <2 <2 <2 <2 <2 <2 1024 
PRVgm 7 <2 <2 <2 <2 <2 <2 <2 2048 
8 <2 <2 <2 <2 16 16 2 512 
9 <2 <2 <2 <2 1024 1024 512 16384 
NYVAC/ 10 <2 <2 <2 <2 2048 2048 1024 8192 
PRVgpSO 11 <2 <2 <2 <2 512 256 128 8192 
12 <2 <2 <2 2 1024 512 512 16384 
13 <2 <2 <2 <2 <2 <2 <2 512 
parent 14 <2 <2 <2 <2 <2 <2 <2 512 
NYVAC 15 <2 <2 <2 <2 <2 <2 <2 1024 
16 <2 <2 <2 <2 <2 <2 <2 2048 
17 <2 <2 32 16 2048 2048 1024 2048 
inacL 18 <2 <2 64 64 2048 2048 512 8192 
PRV 19 <2 2 16 32 512 512 256 2048 
20 <2 <2 2 4 2048 2048 512 8192 
21 <2 <2 <2 <2 <2 <2 <2 4096 
control 22 <2 <2 <2 <2 <2 <2 <2 512 
23 <2 <2 <2 <2 <2 <2 <2 1024 
24 <2 <2 <2 <2 <2 <2 <2 2048 
IWeek 0 - 1st injection 
2^Week 4 - 2nd injection 
^Week 8 - Challenge 
Hg. 2. Radioinimunoprecipitation with lysates of PK-15 cells infected with Indiana-
Fimkhauser (IND-F) strain of pseudorabies virus (PRV) and sera from vaccinated pigs. 
Lane M conesponds to radiolabeled markers with sizes given in kilodaltons to the left 
Lane 1 contains precipitate obtained with serum from a PRV hyperimmunized pig. 
Precipitates obtained with pre-vaccination serum from pig 18 (inacL PRV), 10 
(NYVAC/PRVgp50), 4 (NYVAC/PRVgll), 8 (NYVAC/PRVgUI), or 14 (parent NYVAC) 
are shown in lanes 2,4,6,8, and 10, respectively. Precipitates obtained with serum taken 
4 weeks after the 2nd injection from pig 18,10,4, 8, or 14 are in lanes 3,5,7,9, and 11, 
respectively. Arrows point to proteins with sizes that correspond to glycoproteins gp50 in 
lane 5, gll in lane 7 (3 components glla, glib, and gllc), and glll in lane 9 precipitated 
with the post vaccination sera. 
kDa M 1 2 3 
92.5-
14 J-
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and parent NYVAC groups; it appeared less severe than in the controls but more severe than in 
the gll or gpSO recombinant groups or the inactiva^ PRV group. Pigs in the inactivated PRV 
group were least affected by challenge, having only very mild signs of infection. 
The control and parent NYVAC groups had the highest and longest mean febrile 
responses, with pyrexia of >40®C for 5 days peaking at 41,4®C (Fig. 3). The pigs vaccinated 
with the inactivated PRV preparation had the lowest febrile response with the mean temperature 
never rising above 40° C, although three of four pigs had temperatures > 40°C for 1-3 days. 
Groups receiving either the NYVAC/PRV gll, NYVAC/PRV gUI, or NYVAC/PRV gp50 had 
a fever intermediate between the control and inactivated PRV vaccinated groups, exhibiting 
fever of >40°C for 3,4 and 4 days respectively, with peaks of 40.7°C, 41°C and 40.5°C 
respectively (Fig. 3). 
Significantiy, the PRV challenge appeared to have littie effect on the mean percentage 
daily weight gains of the NYVAC/PRV gll, gp50, and the inactivated PRV vaccine groups 
(Fig. 4). Prior to challenge all pigs had approximately a 2% weight gain per day. From 3 to 7 
days after challenge, pigs in the NYVAC/PRV gll, gp50, and inactivated vaccine groups 
continued to gain weight at approximately the same rate. The weights of pigs in the 
NYVAC/PRV gin and NYVAC parent groups remained relatively static from days 3 to 7 after 
challenge, while those in the control group lost approximately 1% per day during this time 
(Fig. 4). 
Vaccination with recombinant viruses also had a significant effect on virus shedding 
following challenge (Tables 2a,b and 3). Based on 7 successive nasal and pharyngeal swabs, 
taken every other day firom day 1-11 and on day 14 after challenge, the pigs which received the 
gp50 recombinant shed virus on fewer days by either route, compared to controls (mean 4.5 
vs. 6.75 days). Unlike pharyngeal shedding, which followed the above pattern, virus 
excretion fix)m the nasal cavity was less in pigs receiving either the gp50 recombinant or the 
inactivated PRV vaccine than in the controls (Tables 2a,b and 3). 
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Fig. 3. Mean body temperatures after challenge with virulent PRV. 
To determine whether vaccination prevented the establishment of latent PRV infection 
following challenge, pigs were euthanized 4 months after challenge and trigeminal ganglia were 
collected for PCR to detect PRV DNA sequences. Primers used were specific for amplification 
of a 195 bp segment of the essential PRV gll gene. Representative resxilts with PCR-derived 
samples from single animals in each group are shown in Figure 5. Trigeminal ganglia from 23 
of the 24 pigs studied were positive by PCR for PRV gll sequences. Only one pig firom the 
gn recombinant group was PCR negative (data not shown). Thus, the vaccination of pigs with 
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Fig. 4. Mean percent body weight gains after challenge with virulent PRV. 
NYVAC recombinant viruses expressing the individual glycoproteins, gH, gin, or gp50, or 
the inactivated PRV vaccine failed to protect against establishment of latent infection. 
Discussion 
Previously, it was reported that vaccinia virus-based recombinants expressing the PRV 
gn, gin, or gp50 alone or in combination protected pigs clinically against virulent PRV 
challenge (Riviere £t ai., 1992). The recombinant viruses expressing PRV gll and gp50, or 
gn, gin, and gp50 provided the highest level of protection. These results suggested a 
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Table 2a. Virus isolation from nasal swabs after challenge with virulent PRV 
Days 
Group Pig 0 1 3 5 7 9 11 14 21 28 
1 - - 1+ 3+ 3+ - 1+ - - -
NYVAa 2 - 2+ 4+ 4+ 2+ (+) - - - -
PRVgH 3 - - - 2+ 4+ 2+ - - - -
4 - - - 2+ 4+ 4+ 3+ - - -
5 - 2+ 4+ 4+ 4+ 2+ 2+ - - -
NYVAC/ 6 - - 3+ 4+ 3+ 2+ 2+ - - -
PRVgm 7 - 2+ 4+ 4+ 3+ 1+ - - - -
8 - - - 3+ - - - - - -
9 - - 1+ (+) - - (+) - - -
NYVAa 10 - - 1+ 3+ 2+ (+) - - - -
PRVgpSO 11 - - - (+) 1+ - - - - -
12 - - 3+ 4+ 2+ 2+ - - - -
13 - - 4+ 4+ 3+ 2+ - - - -
parent 14 - (+) 4+ 4+ 3+ 4+ 4+ 2+ - -
NYVAC 15 - - - 4+ 4+ 4+ 3+ 2+ - -
16 - - 4+ 4+ 3+ 2+ - - - -
17 - - (+) (+) - - - - - -
inact 18 - 1+ 3+ 4+ 4+ 2+ 1+ - - -
PRV 19 - - 2+ 1+ 2+ - - - - -
20 - - 1+ (+) - - - - - -
21 - - (+) 4+ 4+ 4+ 3-f- (+) - -
control 22 - 2+ 4+ 4+ 2+ 2+ 1+ - - -
23 - - 3+ 4+ 4+ 3+ 2+ - - -
24 - - (+) 3+ 4+ 2+ - - - -
1+ = 1-10 plaques @ 24 hrs.; 2+ = 11-100 plaques @ 24 hrs.; 
3+ = 101-1000 plaques @ 24 hrs.; 4+ = complete CPE @ 24 hrs.; 
(+) = became + after 24 hrs. 
46 
Table 2b. Virus isolation from pharyngeal swabs after challenge with virulent PRV. 
Days 
Group Hg 0 1 3 5 7 9 11 14 21 28 
1 - 2+ 2+ 4+ 2+ (+) (+) - - -
NYVAa 2 - 2+ 3+ 3+ 2+ 1+ 1+ (+) - -
PRVgn 3 
4 
- (+) 2+ 
2+ 
3+ 
2+ 
3+ 
2+ 
1+ 
(+) 
W - - -
5 - 1+ 3+ 3+ 3+ 1+ (+) (+) - -
NYVAC/ 6 - 2+ 3+ 3+ 2+ 1+ 1+ (+) - -
PRVgm 7 - 1+ 4+ 3+ 3+ 3+ 1+ (+) (+) -
8 - (+) 2+ 3+ 2+ - (+) 2+ - -
9 - - 2+ 3+ 1+ - - - - -
NYVAa 10 - (+) 2+ 3+ 2+ 2+ (+) - - -
PRVgpSO 11 
12 
-
(+) 
3+ 
3+ 
2+ 
3+ 
2+ - - -
-
-
13 - (+) 2+ 2+ 3+ 1+ 1+ (+) - -
parent 14 - 2+ 3+ 2+ 3+ 2+ (+) 1+ - -
NYVAC 15 - 1+ 2+ 3+ 2+ 2+ 1+ (+) - -
16 - (+) 2+ 2+ 3+ 2+ 1+ - - -
17 - 1+ 2+ 1+ 1+ (+) - (+) - -
inact. 18 - (+) 2+ 4+ 3+ 2+ (+) - - -
PRV 19 - (+) 4+ 3+ 2+ 2+ (+) - - -
20 - 1+ 3+ 3+ 2+ (+) 1+ (+) - -
21 - 2+ 2+ 3+ 3+ 3+ 2+ (+) - -
control 22 - 2+ 2+ 3+ 3+ 3+ 2+ (+) - -
23 - 3+ 4+ 3+ 3+ 3+ 1+ (+) - -
24 - (+) 2+ 2+ 1+ 2+ 1+ - - -
1+ = 1-10 plaques @ 24 hrs.; 2+ = 11-100 plaques @ 24 hrs.; 
3+ = 101-1000 plaques @ 24 hrs.; 4+ = complete CPE @ 24 hrs.; 
(+) = became + after 24 hrs. 
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Table 3. Summary of the number of days virus was shed after challenge. 
Days Shed Days Shed Overall 
Group Nasal^ Pharyngeal^ Sheddingl'2 
NYVAC/PRVgH 4.00 5.75 6.00 
NYVAC/PRVgm 4.25 6.75 6.75 
NYVAC/PRVgp50 3.25 3.75 4.50 
parent NYVAC 5.00 6.25 6.75 
inacL PRV 3.25 6.25 6.25 
control 5.25 6.75 6.75 
^ Mean number of days per pig based on 7 sampling times. (Pigs were swabbed every other 
day ftom day 1 to day 11 and ^y 14 after challenge.) 
2 Mean number of days PRV shed by either nasal or pharyngeal route. 
synergistic effect of gll and gp50 in inducing protection. Higher levels of protection against 
equine herpesvirus 1 (EHV-1) were also noted in a hamster system using a vaccinia 
recombinant expressing EHV glycoproteins (Guo £t al., 1990). The data presented here and 
by Riviere et al. (1992) encourage the further development of recombinant PRV vaccines, 
which could overcome some of the shortcomings of conventional attenuated or inactivated 
vaccines. Vaccinia recombinants provide a means to 1) eliminate live attenuated PRV vaccines, 
2) develop serological tests to distinguish vaccinated and naturally infected animals, and 3) 
possibly allow vaccination in the presence of maternal immunity. The availability of the highly 
attenuated NYVAC vector also significantiy reduces the risks of such recombinant vaccines. 
NYVAC has been shown to display reduced replication in cells from mice, rabbits, 
equids, humans, and relevant to this study, swine (Tartaglia et al., 1992 and unpublished 
results). NYVAC has been shown to be highly attenuated in vivo compared to several 
established vaccinia virus strains (Tartaglia si M-. 1992 and unpublished observations). 
Despite these attenuated characteristics, it retains the ability to induce immunological responses 
Rg. 5. Amplification of a 195 bp PRVgll specific fragment from the trigeminal ganglia of 
pigs following PRV challenge. rcR aniyses were performed with DNA from trigeminal 
ganglia as described in Materials and Methods. The lane marked bp contains size markers 
with their corresponding number of base pairs indicated to the left Lane 1 is a positive 
control using the Indiana-Funkhauser strain of PRV DNA. Lane 2 is a negative control. 
Lanes 3,4, and 5 contain digested recombinants NYVACyPRVgll, NYVAC/PRVgin, and 
NYVAC/PRV gp50 respectively. Lanes 6-11 contain products using tissue digests of 
trigeminal ganglia from one pig in each experimental group. Lane 6 is from pig 4 (group 1); 
lane 7 from pig 6 (group 2); lane 8 from pig 10 (group 3); lane 9 from pig 15 (group 4); 
lane 10 from pig 18 (group 5); lane 11 fiwm pig 24 (group 6). PGR of trigeminal ganglia of 
unvaccinated unchallenged pigs did not amplify PRVgll-specific sequences. 
b p  1 2 3 4 5 6 7  8  9  1 0  1 1  
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against extrinsic immunogens. For instance, NYVAC-based recombinants have been shown to 
protect swine against Japanese encephalitis virus (Konishi 1992) and horses against 
equine influenza virus (unpublished results). 
We report here protection of swine against PRV challenge by vaccination with 
NYVAC-based recombinants expressing, individually, the PRV gll, gin, or gp50 
glycoproteins. Although vaccination of pigs with all these recombinants, or the inactivated 
PRV vaccine preparation did not prevent the establishment of latent PRV infection following 
challenge (Rg. 5), all four reduced the severity of clinical signs (Figs 3 and 4). Clinical signs 
were least severe in pigs vaccinated with the inactivated PRV vaccine preparation or 
NYVAC/PRV gp50; virus shedding was also shortened in these two groups (Tables 2a,b and 
3). 
Interestingly, the group receiving the NYVAC parent virus (group 4) appeared to be 
less affected by PRV challenge than did the sham vaccinated control group (group 6). It has 
previously been reported that wild-type vaccinia virus administered to mice provides partial 
protection against PRV challenge and is most likely the result of nonspecific immune effector 
mechanisms (Kostfital., 1989). 
Several immunological mechanisms have been implicated in recovery fix)m and 
protection against PRV infection. These include virus neutralizing antibodies (Iglesias al-. 
1990), complement-dependent cytolysis of infected cells (Iglesias stai., 1990), antibody-
dependent cellular cytotoxicity (El Awar and Hahn, 1987; Iglesias fit al-. 1990; Kensinger fit al 
., 1987), natural killer cell activity (Martin and Wardley, 1984), and cytotoxic T lymphocyte 
activity (Zsakfiial., 1989). In this study, the level of PRV VN activity was associated with the 
degree of protection. Animals vaccinated with the inactivated PRV vaccine or NYVAC/PRV 
gp50 had the highest VN titers (Table 1). Animals in these groups also manifested the least 
severe clinical signs. Significant protection however, was also noted for pigs vaccinated with 
NYVAC/PRV gll, despite relatively low VN titers. Therefore, cell-mediated immunity elicited 
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by PRV gn may also have made a contribudon. Although PRV gin has been implicated as 
significant in eliciting protective immunity against PRV (Riviere 1992; Maichioli fit al., 
1988; Ben-Porat £i al., 1986), the gin recombinant did not elicit high VN activity nor did it 
protect as well against disease. Differences in the antigenic properties of gin incorporated into 
the recombinant (strain NIA.3), compared with the challenge strain (IND-F) may be responsible 
for this, especially in view of a previous report describing antigenic drift in the PRV gin (Ben-
Porat fiial-. 1986). 
In summary, we have shown that the NYVAC vector expressing PRV glycoproteins 
elicits protective immune responses in swine. Vaccination with these viruses was well 
tolerated by the animals and no local lesions or systemic reactions resulted from vaccination. 
The NYVAC vector, with its restricted capacity to replicate in ceUs derived from several animal 
species, including man and swine, provides advantages, in that it limits or prevents 
transmission to unvaccinated contacts, and reduces the probability of dissemination within the 
vaccinated animal. Presentiy, NYVAC-based recombinant viruses expressing multiple PRV 
glycoproteins are being further assessed for their safety and efficacy in swine. It will be of 
interest to determine whether combinations of PRV inmiunogens will potentiate the protective 
immune response, as noted previously (Riviere £i al-i 1992), and also limit virus shedding and 
the establishment of latent PRV infection. 
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CHAPTER 3. COMPARISON OF THE PROTECTIVE RESPONSE INDUCED 
BY NYVAC VACCINIA RECOMBINANTS EXPRESSING EITHER 
GPSO or GH AND GP50 OF PSEUDORABIES VIRUS 
A paper published in The Canadian Journal of Veterinary Research 
Susan L. Brockmeier and William L. Mengeling 
Abstract 
A NYVAC vaccinia vector containing genes for pseudorabies virus glycoproteins gll 
and gp50 was administered to pigs to determine if it would have a greater protective effect than 
a vector containing the gene for gp50 alone. Both NYVAC vectors protected pigs sinrilarly 
from virulent pseudorabies virus challenge. 
Introduction 
Pseudorabies (PR), a disease caused by a herpesvirus of the subfamily 
Alphaherpesvirinae, is of significant importance to the swine industry to warrant an eradication 
program. Currently, the recommendation is to use gene deleted "marker" pseudorabies virus 
(PRV) vaccines. Gene deleted vaccines allow vaccination of pigs, which decreases the clinical 
signs of disease and shedding of virulent virus, while also allowing for the differentiation of 
vaccinated fixjm naturally infected animals (1). Vaccinia vectored PRV vaccines have an even 
greater potential for differential testing because the genes for only a few relevant immunogens 
of PRV are inserted into the vaccinia viral genome. In contrast to traditional subunit vaccines, 
vaccinia provides a convenient and less expensive method of delivering the desired antigen, 
and also the potential to induce a cell-mediated immune response through antigen delivery via 
the MHCI pathway. 
The NYVAC vaccinia vector was developed by deleting virulence and host range genes 
fix>m the Copenhagen strain of vaccinia (2). As a result, the NYVAC vector has a reduced 
replicative capacity in tissue culture cells from certain species, including swine and humans, 
and decreased general virulence, addressing some of the safety issues surrounding the use of 
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vaccinia based vaccine candidates (2). To test the possible use for the NYVAC veaor in 
developing a PR vaccine, genes for the glycoproteins gll, gin and gp50 of PRV were insened 
in various combinations into the NYVAC vector. Glycoproteins gll, gITT and gp50 of PRV 
have all been shown to elicit neutralizing antibodies (3). Glycoproteins gll and gp50 are both 
essential for replication of the virus and have been shown to function in viral penetration of the 
cell (gll and gp50) and cell to cell spread of the virus (gll) (3). Glycoprotein gin, although 
not essential, does play a role in adsorption to and release from the cell (3). PRV gll, gin and 
gp50 are homologs of herpes simplex virus-1 gB, gC and gD, respectively. 
We previously tested the immunogenicity of glycoproteins gll, glU, and gp50 singly in 
pigs using the NYVAC vector (4). The previous study indicated gpSO was the most 
immunogenic and protective glycoprotein of the three under the conditions they were tested. 
We also tested the immunogenicity of a NYVAC recombinant which contained all three 
glycoproteins given intramuscularly, as well as orally and intranasally (5). In the latter study, 
there was no evidence that the triple NYVAC recombinant was any more immunogenic than the 
NYVAC recombinant with gp50 alone, but we did not compare them direcdy in the same 
study. Therefore, this study was designed to determine whether the combination of 
glycoproteins gll and gp50 delivered via the NYVAC vector is superior to gp50 alone delivered 
through the NYVAC vector in protecting pigs from virulent PRV challenge. A previous study 
has reported a synergistic effect between gll and gp50 in providing protection from virulent 
PRV challenge in swine (6). These results could impact selection of the most immunogenic 
vaccine that leaves the largest selection of antigens to use for differential testing. 
Materials and methods 
The experimental design for the present study consisted of randomly allocating 12,4-6 
week old male pigs from a PRV negative herd into 3 groups. Two groups were vaccinated by 
giving 2 intramuscular injections in the thigh of 10^ CCID50 of NYVAC/gp50 or 
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NYVAC/gUgpSO, 4 weeks apart The third group was a non-vaccinated control group. Virus 
neutralizing andbody titres for PRV were detemuned as previously described in serum samples 
obtained pre-vaccination, 4 weeks after the first vaccination, 4 weeks after the second 
vaccination and after challenge (7). Challenge consisted of administering 10® plaque forming 
units of Indiana-Funkhauser strain of PRV oronasally, 4 weeks after the second vaccination. 
Protection from challenge was assessed by recording clinical signs, rectal temperatures, body 
weight, and viral shedding via nasal and throat swabs taken every other day for approximately 
2 weeks after challenge. Procedures for collection of nasal and throat swabs and detection of 
PRV from those swabs were as previously described (4). The Canadian Council on Animal 
Care's Guide to the Care and Use of Experimental Animals was followed in conducting this 
experiment 
Results and discussion 
Both NYVAC recombinants used in this experiment express their respective PRV 
glycoproteins as determined through indirect fluorescent antibody testing of infected cell 
cultures using anti gll or gp50 antibodies (data not shown). 
Virus neutralizing (VN) antibodies for PRV were found in pigs vaccinated with both of 
the NYVAC recombinants. As was the case in previous experiments, two injections were 
needed in most cases before neutralizing antibody was detected (4,5). The geometric mean VN 
titers for the respective groups are given in Table I. The titres for the two groups receiving the 
NYVAC recombinants were similar and the control group did not develop neutralizing antibody 
to PRV until after challenge. Indirect fluorescent antibody titers for gp50 were determined by 
reacting 4-fold dilutions of the immune serums after second injection with cell cultures infected 
with NYVAC/gp50 to determine if the same antibody response to gp50 was elicited by both 
recombinants. Immune serum from pigs vaccinated with the NYVAC parent virus was used as 
a control to assess if anti-NYVAC antibody contributed to the fluorescent reaction. Slight 
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fluorescence was only seen at the lowest dilution with the anti-NYVAC antiserum. Results 
indicated that the level of anti-gpSO antibody in both groups receiving NYVAC recombinants 
was similar (data not shown). Also, anti-gll antibodies were shown to be present in the serum 
of pigs given the NYVAC/gII,gp50 recombinant but not pigs given the NYVACygpSO 
recombinant through radioimmunoprecipitation using immune serum and PRV infeaed cell 
lysate (data not shown). 
Table I. Geometric mean (log2) virus neutralizing antibody titers for PRV in sera collected 
before vaccination, and at intervals after vaccination and challenge 
Group Pre-Vaccination 4 weeks after 1st 4 weeks after 2nd 6 weeks after 
Vaccination vaccination challenge 
gpSO 0 0.25 7.5 >12 
gn,gp50 0 0 6.5 >12 
control 0 0 0 >11 
All pigs developed signs of PR after challenge including anorexia, depression, 
vomiting, and upper respiratory signs with pigs in the control group developing the most 
severe signs. One pig from the control group developed seizures and another pig from the 
control group died. The mean rectal temperatures of the groups after challenge did not differ 
significandy (Rgure 1). This is in contrast to the previous experiment in which the NYVAC 
recombinants with the single glycoprotein inserts were given, where all groups receiving 
NYVAC recombinants containing PRV genes had lower rectal temperatures than control 
groups (4). A possible explanation for the lack of difference in temperatures in this experiment 
may be the higher challenge inoculum given (10^ plaque forming units vs 10^ plaque forming 
units). The pigs in the groups receiving the NYVAC recombinants lost less weight and 
recovered body weight quicker than the controls (Figure 2). The pigs receiving the NYVAC 
recombinants had a significantly higher weight increase from challenge to day 17 after 
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challenge, than did the controls (p=0.05 using Student's t-test). In fact, the average weight of 
the control pigs on day 17 was lower than their average weight on the day of challenge. There 
was no statistical difference in weight gain after challenge for the two groups receiving the 
NYVAC recombinants. Both groups receiving the NYVAC recombinants also shed virus for 
significantly fewer days than did the control pigs (pcO.Ol for NYVAC/gp50 and p=0.02 for 
NYVAC/gn,gp50 using Student's t-test), but there was no significant difference between the 
groups receiving the NYVAC recombinants (Table II). 
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Table IL Summary of the number of days PRV was shed after challenge 
Route gp50 gn,gp50 control 
Nasal 3.751 3.00 5.67 
Throat 3.50 5.25 6.33 
Either Route 4.50 5.25 6.70 
1 Mean number of days per pig based on 7 sampling times. (Pigs were swabbed every other 
day from day 1 to day 11 and day 14 after challenge.) 
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In this study there did not appear to be a difference in protection afforded by the 
combination of PRV glycoproteins gH and gp50 over the protection elicited by just gp50. This 
may be significant in differential testing for the eradication program. Currently, inactivated or 
attenuated marker vaccines used in differential testing are limited to deletions of nonessential 
glycoprotein genes but with a vaccinia vectored subunit vaccine a differential test for an 
essential gene such as gll is possible. Also, the live viral vector maintains the advantages of 
attenuated vaccines over inactivated virus or subunit vaccines. Since gQ is an essential gene 
and the most abundant glycoprotein of the PRV genome it should be an excellent choice for 
differential testing (3). 
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CHAPTER 4. VACCINATION WITH RECOMBINANT VACCINIA VIRUS 
VACCINES EXPRESSING GLYCOPROTEINS OF PSEUDORABIES 
VIRUS IN THE PRESENCE OF MATERNAL IMMUNITY 
A paper submitted to Veterinary Microbiology 
Susan L. Brockmeier, Kelly M. Lager, and William L. Mengeling 
Abstract 
Piglets which had received colostral immunity to pseudorabies virus (PRV) were 
divided into 4 groups and vaccinated with a NYVAC vaccinia recombinant expressing 
glycoprotein gD of PRV, a NYVAC recombinant expressing glycoprotein gB of PRV, an 
inactivated PRV vaccine, or no vaccine. The piglets were vaccinated twice, 3 weeks apart, 
beginning at approximately 2 weeks of age and later challenged with virulent PRV oronasally. 
Piglets that received NYVAC/gB were well protected based on lack of mortality, lower 
temperature responses, lack of weight loss and decreased viral shedding after challenge. These 
results indicate a strategy for stimulating active immune response while still under the 
protection of matemal immunity. 
Introduction 
Pseudorabies (PR) is an enzootic disease of swine in many parts of the world which 
causes mortality of newborn piglets, respiratory disease and in some cases matemal 
reproductive failure (Kluge et aL, 1992). The disease is thought to be perpetuated through 
latent viral infections from which the virus can occasionally reactivate and be shed back into the 
environment (Kluge et al., 1992). Although vaccination does not prevent viras replication or 
latency, it can protect against clinical disease and decrease the amount of virus shed into the 
environment (Kluge et al., 1992). As is the case with many vaccines, immunity to PR virus 
(PRV) derived from the dam interferes with active immunization of the piglets until it decreases 
to a level that often leaves piglets unprotected. No vaccination strategies to date have been able 
to totally overcome this obstacle (De Leeuw and Van Oirschot, 1985; De Leeuw et al., 1982; 
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De Smet et al., 1994; Kit et al., 1993; McCaw and Xu, 1993; Vannier, 1985; Vannier, 1986; 
Van CMrschot, 1987; Van Oiischot, 1991; Van Oiischot and De Leeuw, 1985). 
The purpose of this study was to detennine if a recombinant vaccinia virus vacdne 
could present PRV andgens to the piglet's immune system, stimulating an active immune 
response in the presence of maternally derived antibody to PRV. The recombinants chosen for 
this study express either glycoprotein gB (NYVAC/gB) or gD (NYVAC/gD) of PRV. Both 
recombinants were chosen because in past studies both induced protection, but the gD 
recombinant induced higher virus neutralizing antibody titers, whereas the gB recombinant 
protected even though only low to moderate virus neutralizing titers were produced 
(Brockmeier et al., 1993). Thus, there may be predominantiy different mechaiusms of immune 
protection induced by these immunogens and they may have differing abilities to induce 
protection in the face of maternal immunity. 
Materials and methods 
Experimental design 
Two gilts were vaccinated with an inactivated PRV vaccine (iPRV) 6 and 2 weeks prior 
to their predicted farrowing dates and 2 gilts were left as non-vaccinated controls. After 
farrowing, the piglets were allowed to nurse normally to obtain colostral immunity and were 
weaned at 4 weeks of age. The piglets from each litter were randomly divided into 4 groups 
and received either NYVACVgD, NYVACygB, iPRV vaccine, or no vaccine. Group 
identification, number of piglets per group, and vaccine treatment is summarized in table 1. 
Two injections of each vaccine were given, the first at approximately 2 weeks of age and the 
second 3 weeks after the first The gilts were housed in isolation facilities and then removed at 
the time of weaning. The piglets were left in the isolation room in which they farrowed until 
the end of the experiment Based on past studies we have found no transmission of the 
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NYVAC vector to occur between vaccinated and nonvaccinated animals (Mengeling et al., 
1994 and unpublished data). 
The piglets were challenged oronasally with virulent PRV, 5 weeks after the second 
vaccinadon. After challenge, the piglets were monitored daily for the next 11 days for clinical 
signs and rectal temperatures. The pigs were weighed 10 days prior to challenge, on the day of 
challenge, and on days 3,7,10, and 17 after challenge. Oropharyngeal swabs were taken 
every other day fix)m day 1 through 11 after challenge to determine viral shedding. 
Table 1. Experimental groups (number of animals) 
Gilt vaccine Hglet vaccine 
1. iPRV (2) la. NYVAagD (4) 
lb. NYVAC/gB (4) 
Ic. iPRV(4) 
Id. none (4) 
2. none (2) 2a. NYVAC/gD (5) 
2b. NYVAC/gB (5) 
2c. iPRV(5) 
2d. none (4) 
Serum samples were obtained from the gilts prior to vaccination, 4 weeks after the first 
vaccination and 24 hours after farrowing (3 to 4 weeks after the second vaccination). Serum 
samples from the piglets were obtained prior to vaccination, 3 weeks after the first vaccination, 
5 weeks after the second vaccination (just prior to challenge) and 17 days after challenge. 
Differences between experimental groups with regard to viras neutralizing (VN) 
antibody titers and weight responses on day 7 after challenge with virulent virus were analyzed 
statistically, using Student's t-te&t. 
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Virus and cells 
The inactivated PRV vaccine used to vaccinate the gilts and piglets was the conunercial 
product PRV/Maiker Gold-KV (SyntroVet Inc.), which has deletions in the gE and gG 
glycoprotein genes. A 2 ml dose was administered intramuscularly. 
The NYVAC strain of vaccinia virus is an attenuated vaccinia vims vector derived by 
genetically engineering the deletion of putative virulence and host range genes from the 
Copenhagen vaccinia virus vaccine strain (Tartaglia et aL, 1992). NYVAC vaccinia 
recombinants which express either gB or gD were used to vaccinate the piglets (NYVAC/gB 
and NYVAC/gD). A 1 ml dose of lO^-^ median cell culture infective doses (CCID50) was 
administered intramuscularly. NYVAC-based viruses were propagated in primary chicken 
embryo fibroblasts and titrated on bovine embryonic spleen cells (BESp) using CCID50 as 
described previously (Brockmeier et al., 1993). 
Two mis of the Indiana-Funkhauser strain of PRV, containing 10^ plaque forming 
units/ml, were adnoinistered oronasally to challenge immunity of the piglets after vaccination. 
An established porcine kidney cell line, PK-I5, was used to propagate and titrate PRV 
challenge virus and PRV titrations were performed by plaque assay (Mengeling, 1991). 
Virus isolation and antibody titration 
Vniis isolation and titration of PRV from oropharyngeal swabs were performed as 
described previously using BESp and PK-15 cells respectively (Brockmeier et al., 1993). 
Titration of VN antibodies in the serum of pigs was performed using PK-15 cells as 
previously described (Mengeling, 1991). 
Sera from all piglets collected prior to vaccination, 5 weeks after the second 
vaccination, and 17 days after challenge were tested for antibodies to PRV glycoprotein gE 
using the Herdcheck: Anti-PRV-gI(gE) test kit (IDEXX laboratories Inc.). 
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Results 
Antibody response 
The gilts were ftee of VN andbody to PRV prior to vaccination and non-vaccinated gilts 
remained PRV antibody negative throughout the experiment The vaccinated gilts had VN 
titers of 32 and 256 after farrowing. All piglets bom to vaccinated gilts had VN antibody titers 
prior to vaccination and the geometric mean VN antibody titers among the groups were similar 
(Table 2). The piglets bom to non-vaccinated dams had no detectable VN antibody to PRV at 
the time of vaccination. All piglets remained clinically normal following both vaccinations. 
VN titers 3 weeks after the first vaccination were lower than pre-vaccination titers for 
all groups with maternal immunity and there was no significant difference in antibody titers 
between the vaccinated and non-vaccinated piglets (Table 2). Of the seronegative piglets. 
Table 2. Geometric mean log2 PRV neutralizing antibody titers of piglets bom to vaccinated 
and non-vaccinated gilts (range) 
maternal 
piglet vaccine immunity day 0^ day2lb day 56^ day 73^1 
NYVAC/gD yes 7.75 (5-10) 6.00 (3-8) 6.25 (4-7) 18.00 (17-19) 
no <1 0.50 (<1-1) 10.20(10-11) 18.00 (18) 
NYVAC/gB yes 8.75 (7-10) 6.50 (6-7) 4.75 (3-6) 13.75 (11-18) 
no <1 <1 3.20 (2-4) 14.00 (12-17) 
iPRV yes 9.00 (8-10) 6.25 (6-7) 6.50 (6-8) 14.30 (14-15) 
no <1 6.60 (5-8) 11.20(10-12) 16.00 (15-18) 
none yes 8.75 (8-9) 6.25 (6-7) 3.25 (3-4) 13.00(11-16) 
no <1 <1 <1 10.70 (10-12) 
^Pre-vaccination 
'Twenty-one days after first vaccination 
cThirty-five days after second vaccination 
^Seventeen days after challenge 
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group 2c had VN antibody titers which ranged firom 32 to 256 after the first vaccination, 3 of 
the S piglets in group 2a responded after die first vaccination with titers of 2, and none of the 
piglets of group 2b had titers after the first vaccination. Group 2d piglets remained 
seronegative until challenge. 
Five weeks after the second vaccination, groups la and Ic had mean antibody titers just 
slightiy higher than titers prior to the second vaccination and significandy higher than their non-
vaccinated counterparts in group Id (p<0.05). Piglets in group lb had mean antibody titers 
lower than titers prior to the second vaccination but 3-fold higher than their non-vaccinated 
counterparts (Table 2). The titers of group 2a and 2c, were significantly higher than the titers 
of group la and Ic (p<0.01). Group lb piglets had 3-fold higher mean antibody response than 
group 2b piglets. 
There was an increase in the antibody titers of all piglets after challenge. The group 
receiving NYVAC/gD had the highest increase in antibody titer after challenge (Table 2). 
Challenge 
In groups lb, 2a, 2b and 2c, clinical signs of disease after oronasal exposure to virulent 
pseudorabies consisted mainly of mild upper respiratory signs and transient anorexia. Signs of 
disease seen in groups la, Ic, Id, and 2d were in general more severe consisting of severe 
respiratory distress, anorexia, lethargy, vomiting, and seizures. Groups la and Ic both had 
one piglet die on day 5 and 9 post challenge respectively, as did the non-vaccinated groups Id 
and 2d on days 7 and 8, respectively. 
All vaccines were similarly protective when given to piglets that were seronegative prior 
to vaccination. Group 2a, 2b and 2c piglets, on average, did not loose weight after challenge 
and weight gains were significantly better compared to group 2d piglets (pcO.Ol) which lost 
considerable weight and had still not, as a group, regained their pre-challenge weight by the 
end of the experiment (Fig. 1). Group 2a, 2b and 2c piglets had lower temperature responses 
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Rg. 1. Mean percent weight gain before and after challenge with virulent PRV in seronegative 
piglets vaccinated with N\VAC/gD (2a), NYVAC/gB (2b), iPRV (2c) or not vaccinated (2d). 
and shed less virus after day 3 post challenge than did their non-vaccinated counterparts in 
group 2d (Figs. 2 and 3). 
After challenge, piglets in groups la and Ic which had maternal immunity and were 
vaccinated with NYVAC/gD and iPRV did not perform as well as piglets in 2a and 2c which 
were seronegative piglets vaccinated with the same vaccines. Piglets in groups la and Ic had 
similar temperature responses and weight losses as non-vaccinated piglets in group Id (Figs. 4 
and 5). Each of these groups averaged temperatures greater than 41® C for 4 days and had 
weight losses of 1 to 3.25% body weight- The weight gains of these pigs remained stunted 
through the end of the experiment By day 7, however, groups la and Ic were shedding less 
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Hg. 2. Mean temperature response after challenge with virulent PRV in seronegative piglets 
vaccinated with NYVAC/gD (2a), NYVAC/gB (2b), iPRV (2c) or not vaccinat^ (2d). 
virus, on average, than the non-vaccinated groups (Fig. 6). 
Piglets in group lb had an average temperature of greater than 41° C for only I day and 
never lost weight or appeared to have a growth arrest after challenge (Figs. 4 and 5). The 
piglets in this group had significandy better weight gains than piglets in group Id (pcO.OS). 
Individually, 1 pig had lost weight at day 3 after challenge but had recovered by day 7. Piglets 
in group lb also shed less virus, on average, than the non-vaccinated groups after day 7 post 
challenge (Hg. 6). The temperature response, weight response, and viral shedding pattern of 
the piglets in groups lb was similar to those of group 2b, the seronegative piglets which 
received the same vaccine (Hgs. 1-6). 
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Rg. 3. Mean viral shedding curves after challenge with virulent PRV in seronegadve piglets 
vaccinated with NYVAC/^ (2a), NYVAC/gB (2b), iPRV (2c) or not vaccinat^ (2d). 
(Df the 2 non-vaccinated groups, the weight loss on days 7,10 and 17 appeared more 
severe for group 2d piglets which had no maternal immunity as compared to group Id piglets 
which had maternal immunity (Figs. 1 and 4). 
Differential gE antibody testing 
All piglets tested negative for antibody to gE prior to vaccination and after the second 
vaccination. All piglets tested positive for antibody to gE after challenge. 
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Fig. 4. Mean percent weight gain before and after challenge with virulent PRV in maternally 
immune piglets vaccinated with NYVAC/gD (la), NYVAC/gB (lb), iPRV (Ic) or not 
vaccinat^ (Id). 
Discussion 
In this experiment the piglets had good maternally derived antibody titers and they 
were vaccinated at an early age making this a good test of the ability of the vaccines to stimulate 
a response. The NYVAC/gD and iPRV vaccines were able to stimulate an antibody response 
in the piglets and they decreased shedding after challenge exposure, indicating that they were 
able to stimulate active immunity. Although the piglets were vaccinated twice, previous 
experiments have shown that with NYVAC vectors two injections are neccessary to induce a 
measurable VN antibody response (Brockmeier et al., 1993). This is not the case with the 
iPRV vaccine, where one vaccination is capable of stimulating a measurable immune response. 
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Rg. 5. Mean temperature response after challenge with virulent PRV in maternally immune 
piglets vaccinated with NYVAC/gD (la), NYVAC/gB (lb), iPRV (Ic) or not vaccinated (Id). 
Thus with the iPRV, it is possible that the first vaccination was ineffective but the second 
vaccination initiated an immune response when the maternal antibody level was lower. 
Although there was a response to the NYVAC/gD and iPRV vaccines, seronegative piglets had 
significantiy higher antibody titers than seropositive animals vaccinated twice with these 
vaccines. Thus, there was a partial interference with active immunity in the face of maternally 
derived antibody and this may be why these vaccines inadequately protected against clinical 
disease. 
Piglets vaccinated with NYVAC/gB had VN antibody titers slighdy higher than their 
non-vaccinated counterparts and the seronegative piglets vaccinated with this vaccine. These 
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Hg. 6. Mean viral shedding curves after challenge with virulent PRV in maternally inmiune 
piglets vaccinated with NYYAC/gD (la), NYVACVgB (lb), iPRV (Ic) or not vaccinated (Id). 
piglets were well protected fix)m virulent challenge with PRV. There may be several reasons 
why vaccination with NYVACVgB was able to stimulate an active immune response in the 
presence of maternally derived antibodies, as compared to the response to NYVAC/gD which 
was diminished under the same circumstances. It is possible that the level of antibody to gB is 
not as high as to gD in the colostrum of the dams. Another possibility is that other immune 
mechanisms besides VN are responsible for the protective response induced by gB. 
Mechanisms such as cell-mediated immunity may not be blocked to the same extent that 
antibody response is in the presence of matemally derived immunity. 
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The low levels of maternal antibody in group Id present at the time of challenge may 
have offered slight protection because the weight loss in these animals did not appear as 
dramatic as for the seronegative piglets in group 2d. 
These results indicate that recombinant vaccinia vaccines are able to circurmrent the 
inhibition of active immunity caused by maternally derived immunity. The results also indicate 
that the choice of antigen may be very important to the success of such a strategy. More work 
needs to be done to determine the mechanisms by which active immuiuty can be induced under 
these circumstances and which antigens are best able to stimulate these conditions. 
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CHAPTER 5. SUCCESSFUL PSEUDORABIES VACCINATION IN 
MATERNALLY IMMUNE PIGLETS USING RECOMBINANT 
VACCINIA VIRUS VACCINES 
A paper submitted to Research in Veterinary Science 
Susan L. Brockmeier, Kelly M. Lager, and William L. Mengeling 
Abstract 
Three gilts were vaccinated with a NYVAC vaccinia recombinant expressing 
glycoprotein gD of pseudorabies virus (PRV) (NYVAC/gD). After fairowing, the piglets were 
allowed to nurse normally to obtain colostral immunity and then were divided into 4 groups, 
receiving NYVAC/gD, a NYVAC recombinant expressing glycoprotein gB of PRV 
(NYVAC/gB), an inactivated PRV vaccine (iPRV), or no vaccine. The piglets were vaccinated 
twice, 3 weeks apart beginning at approximately 2 weeks of age and later challenged with 
virulent PRV oronasally. Piglets that received NYVAC/gB or iPRV were the best protected on 
the basis of lower mortality, reduced febrile response, weight gain and reduced shedding of 
PRV after challenge. These results indicate that the use of recombinant viral vaccines offer an 
effective strategy for stimulating active immunity in the presence of maternal antibody. 
Introduction 
Pseudorabies (PR) is an enzootic disease in many parts of the world which causes 
mortality of newborn pigs, respiratory disease and in some cases maternal reproductive failure 
(Kluge et al 1992). The disease is thought to be perpetuated through latent viral infections 
from which the virus can occasionally reactivate and be shed back into the environment (Kluge 
etall992). 
Vaccines have traditionally been important in controlling the signs of infection with PR 
virus (PRV). Although vaccines do not prevent replication or latent infection after experimental 
nasal challenge, studies have shown that vaccination decreases viral shedding and increases the 
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exposure necessaiy to initiate an infection (Kluge et al 1992). Thus vaccines can play an 
important role in eradication programs by helping decrease the transmission of the virus. The 
role of vaccines was further bolstered with the advent of gene deletion or marker vaccines that 
can differentiate vaccinated from naturally infected animals. 
There is still one aspect of vaccination programs for pseudorabies that is a problem. 
Sows can be protected through vaccination and pass maternal antibodies to their piglets in their 
colostrum protecting them for a period of time. Unfortunately, maternally derived immunity 
also interferes with active immunization of the piglets until it decreases to a level that often 
leaves the piglets unprotected. In past experiments, no vaccination schemes have been totally 
able to overcome the suppression of an active immune response caused by passively acquired 
immunity (De Leeuw et al 1982, De Leeuw and Van Oirschot 1985, De Smet et al 1994, Kit et 
al 1993, McCaw and Xu 1993, Van Oirschot and De Leeuw 1985, Van Oirschot 1987, Van 
Oirschot 1991, Vanmer 1985, Vannier 1986). 
The purpose of this study was to determine if piglets could be actively immunized with 
recombinant vaccinia virus PR vaccines or an inactivated PRV vaccine after nursing immune 
sows which had received a recombinant vaccinia virus vaccine. Three different vaccines were 
chosen to give to the piglets. The NYVAC vaccinia virus recombinant expressing glycoprotein 
gD of PRV (NYVAC/gD) was given to the dams as well as piglets because in past smdies it 
induced high virus neutralizing (VN) antibody titers and protected well when given to 
seronegative pigs (Brockmeier et al 1993). With the possibility that the immune response to 
gD would be blocked by the passively acquired antibodies fit>m the dam, a NYVAC 
recombinant expressing glycoprotein gB of PRV (NYVACVgB) was also chosen. This would 
also give insight as to whether passively acquired antibodies to the vaccinia vector would 
interfere with the active immune response in the piglets. And finally an inactivated PRV 
vaccine (iPRV) was chosen to see if a protective immune response could be induced in the 
piglets with a full complement of PRV proteins when antibody to just gD was present. 
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Materials and methods 
Experimental design 
Three gilts were vaccinated with NYVACVgD 6 and 2 weeks prior to their predicted 
farrowing dates and 2 gilts were left as non-vaccinated controls. After farrowing, the piglets 
were allowed to nurse nonnally to obtain colostral immunity and weaned at 4 weeks of age. 
The piglets fitom each litter were randomly divided into 4 groups, and received either 
NYVAC/gD, NYVAC/gB, iPRV, or no vaccine. Group identification, number of piglets per 
group, and vaccine treatment is summarized in table 1. Two injections of each vaccine were 
given to the piglets, the first at approximately 2 weeks of age and the second 3 weeks after the 
first. The gilts were housed in isolation facilities and then removed at the time of weaning. 
The piglets were left in the isolation rooms in which they farrowed until the end of the 
experiment. Past studies have shown no transmission of the NYVAC vector to occur between 
vaccinated and non-vaccinated animals (Mengeling et al 1994a and unpublished data). 
Table 1. Experimental groups (number of animals) 
Gilt vaccine Piglet vaccine 
1. NYVAOgD (3) la. NYVAagD (6) 
lb. NYVAC/gB (6) 
Ic. iPRV(6) 
Id. none (6) 
2. none (2) 2a. NYVAC/gD (5) 
2b. NYVAC/gB (5) 
2c. iPRV(5) 
2d. none (4) 
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The piglets were challenged with virulent PRV oronasally, 5 weeks after the second 
vaccination. After challenge the piglets were nuxutored daily for the next 11 days for clinical 
signs and rectal temperatures. The piglets were weighed 10 days prior to challenge, on the day 
of challenge, and on days 3,7,10, and 17 afiter challenge. Oropharyngeal swabs were taken 
just prior to challenge and on days 1, 3,5,7, 9 and 11 after challenge to determine the extent 
of viral shedding. 
Serum samples were obtained from the gilts prior to vaccination, 4 weeks after the first 
vaccination and 24 hours after farrowing. Serum samples from the piglets were obtained prior 
to vaccination, 3 weeks after the first vaccination, 5 weeks after the second vaccination (just 
prior to challenge) and 17 days after challenge. 
Differences between experimental groups with regard to VN antibody titers and weight 
responses on day 7 after challenge with virulent virus were analyzed statistically, using 
Student's t-tesL 
Virus and cells 
The inactivated PRV vaccine used to vaccinate the piglets was the commercial product 
PRV/Marker Gold-KV (SyntroVet Inc.), which has deletions in its gE and gG glycoprotein 
genes. A 2 ml dose was administered intramuscularly. 
The NYVAC strain of vacciiua virus is an attenuated vaccinia virus vector derived by 
genetically engineering the deletion of putative virulence and host range genes from the 
Copenhagen vaccinia virus vaccine strain (Tartaglia et al 1992). A 1 ml dose of 10^-^ median 
cell culture infective doses (CCIDso) was administered intramuscularly to the gilts 
(NYVACygD) or piglets (NYVACVgB or NYVACVgD). NYVAC-based viruses were 
propagated in primary chicken embryo fibroblasts and titrated on bovine embryonic spleen cells 
(BESp) using CCID50 as described previously (Brockmeier et al 1993). 
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Two ml of the Indiana-Funkhauser strain of PRV, containing 10® plaque forming 
units/ml, were adnunistered oronasally to challenge immunity of the piglets after vaccination. 
An established porcine kidney cell line, PK-15, was used to propagate and titrate PRV 
challenge virus and PRV titrations were performed by plaque assay (Mengeling 1991). 
Virus isolation and antibody titration 
Virus isolation and titration of PRV from oropharyngeal swabs were performed as 
described previously using BESp and PK-15 cells respectively (Brockmeier et al 1993). 
Titration of VN antibodies in the serum of pigs was performed using PK-15 cells as 
previously described (Mengeling 1991). 
Sera from all piglets collected prior to vaccination, 5 weeks after the second 
vaccination, and 17 days after challenge were tested for antibodies to PRV glycoprotein gE 
using the Herdcheck: Anti-PRV-gI(gE) test kit (IDEXX Laboratories Inc.). 
Results 
Antibody response 
All gilts were free of VN antibody to PRV prior to vaccination and the non-vaccinated 
gilts remained PRV antibody negative throughout the experiment. The 3 vaccinated gilts had 
VN titers of 256,1024 and 4096 after farrowing. The VN antibody titers at the time of 
vaccination in piglets bom to vaccinated dams ranged ftom 128 to 8192 and the geometric 
mean titers for the groups of these piglets ranged fix)m to 2^0 (Table 2). All piglets bom to 
non-vaccinated dams had no detectable VN antibody to PRV at the time of vaccination. All 
piglets remained clinically normal following both injections. 
Three weeks after the first vaccination, all VN antibody titers in the piglets with 
maternal immunity were lower than on the day of vaccination and there were no significant 
differences between vaccinated and non-vaccinated groups of piglets (Table 2). Of the 
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Table 2. Lo^ geometric mean PRY neutralizing antibody dters of piglets bom to vaccinated 
and non-vaccinated gilts (range) 
piglet vaccine maternal 
immunity day 0* day 21*' day 56® day 73«^ 
NYVACVgD yes 10.0(8-13) 8.3(7-10) 6.2 (4-8) 16.5 (15-19) 
no <1 0.5(<1-1) 10.2(10-11) 18.0 (18) 
NYVAC/gB yes 10.0(8-13) 8.0(7-10) 5.3 (3-6) 15.5 (12-18) 
no <1 <1 3.2 (2-4) 14.6 (12-17) 
iPRV yes 9.5(7-11) 7.8(6-10) 6.3 (6-7) 14.0 (13-15) 
no <1 6.6 (5-8) 11.2(10-12) 16.0 (15-18) 
none yes 9.8(9-13) 7.5(6-10) 3.8 (2-6) 11.0 (11) 
no <1 <1 <1 10.7(10-12) 
®Pre-vaccination 
twenty-one days after first vaccination 
Thirty-five days after second vaccination 
'^ Seventeen days after challenge 
seronegative piglets, group 2c had VN antibody titers which ranged from 32 to 256 after the 
first vaccination, 3 of the 5 piglets in group 2a responded after the first vaccination with titers 
of 2, and none of the piglets of group 2b had titers after the first vaccination. Group 2d piglets 
remained seronegative until challenge. 
With regard to the piglets with maternal immuniQr, antibody titers after the second 
vaccination were, on average, lower for all groups compared to the titer's prior to the second 
vaccination. However, the vaccinated piglets in group la and Ic had significantiy higher mean 
antibody responses than did their non-vaccinated counterparts in group Id (pcO.OS) (Table 2). 
The mean titer of piglets in group lb was higher than that of group Id but not significantiy 
higher (p<0.1). The titers of group 2a and 2c, were significantly higher than the titers of group 
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la and Ic (p<0.01). Group lb piglets had significandy higher mean antibody response than 
group 2b piglets (pcO.Ol). 
The antibody titers for all piglets were higher after challenge. The titers for the 
vaccinated pigs were greater than the non-vaccinated pigs and were highest for the piglets 
vaccinated with NYVAC/gD (Table 2). 
Challenge 
All piglets developed clinical signs of pseudorabies which ranged from mild upper 
respiratory signs to severe respiratory distress, anorexia, lethargy, vomiting and seizures. The 
severity of clinical signs varied among the groups, with group la and the non-vaccinated 
groups Id and 2d experiencing the most severe signs while the other vaccinated groups tended 
to have milder signs of disease. Group la had 2 piglets die, 1 on day 6 and the other on day 
14 after challenge. Group Id had 5 piglets die; 1 on day 5,2 on day 6 and 2 on day 11 after 
challenge. Group 2d had 1 pig die on day 8 after challenge. 
All vaccines were similarly protective when given to piglets that were seronegative prior 
to vaccination. Group 2a, 2b and 2c piglets, on average, did not loose weight after challenge 
and weight gains were significandy better compared to group 2d piglets (p<0.01) which lost 
considerable weight and had still not, as a group, regained their pre-challenge weight by the 
end of the experiment (Fig 1). Group 2a, 2b and 2c piglets had lower temperature responses 
and shed less virus after day 3 post challenge than did their non-vaccinated counterparts in 
group 2d (Figs 2 and 3). 
After challenge, piglets in group la which had maternal immunity and were vaccinated 
with NYVACVgD did not perform as well as piglets in 2a which were seronegative piglets 
vaccinated widi the same vaccine. In fact, there was no significant difference in the average 
weight loss between groups la and Id and temperature response of piglets in group la was 
similar to that of non-vaccinated piglets (Figs 4 and 5). The piglets of group la did shed less 
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Rg. 1. Mean percent weight gain before and after challenge with virulent PRV in seronegative 
piglets vaccinated with NWAC/gD (2a), NYVAC/gB (2b), iPRV (2c) or not vaccinated (2d). 
virus after day 5 post challenge than did non-vaccinated piglets (Fig 6). Piglets vaccinated with 
NYVAC/gB or iPRV which had prior maternal immunity (groups lb and Ic) had a lower 
temperature response, significantly less weight loss (p<0.02), and shed less virus after day 3 
post challenge, on average, than non-vaccinated piglets (Figs 4,5 and 6). The temperature 
response, weight response, and viral shedding pattern of the piglets in groups lb and Ic were 
similar to those of groups 2b and 2c which were seronegative piglets which received these 
vaccines (Figs 1-6) and there was no difference between lb and Ic in providing protection. 
There also was no difference in severity of disease between the 2 non-vaccinated groups Id 
and 2d. 
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Fig. 2. Mean temperamre response after challenge with virulent PRV in seronegative piglets 
vaccinated with NYVAC/gD (2a), NYVAC/gB (2b), iPRV (2c) or not vaccinat^ (2d). 
Differential gE antibody testing 
All piglets tested negative for antibody to gE prior to vaccination and after the second 
vaccination. All piglets tested positive for antibody to gE after challenge. 
Discussion 
The purpose of this experiment was to determine if recombinant vaccinia virus vaccines 
or a conventional vaccine could be used to vaccinate piglets with maternally derived immunity 
from Ham<t vaccinated with one of the recombinant vaccines. In past experiments, no 
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Rg. 3. Mean viral shedding curves after challenge with virulent PRV in seronegative piglets 
vaccinated with NYVAC/^ (2a), NYVAC/gB (2b), iPRV (2c) or not vaccinat^ (2d). 
vaccination schemes have been totally able to overcome the suppression of an active immune 
response caused by passively acquired immunity (De Leeuw et al 1982, De Leeuw and Van 
Oirschot 1985, De Smet et al 1994, Kit et al 1993, McCaw and Xu 1993, Van Oirschot and De 
Leeuw 1985, Van Oirschot 1987, Van Oirschot 1991, Vaimier 1985, Vannier 1986). 
Intranasal vaccination of maternally immune piglets with attenuated strains of PRV has induced 
partial protection but it is less than the protection following administration of vaccine to 
seronegative pigs (De Leeuw et al 1982, De Leeuw and Van Oirschot 1985, McCaw and Xu 
1993, Van Oirschot and De Leeuw 1985, Van Oirschot 1987, Van Oirschot 1991, Vannier 
1986). This makes it difficult to know when to vaccinate piglets to get an adequate active 
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Hg 4: Mean percent weight gain before and after challenge with virulent PRV in maternally 
immune piglets vaccinat^ with NYVAC/gD (la), NYVAC/gB (lb), iPRV (Ic) or not 
vaccinal^ (Id). 
immune response. The higher the level of passively acquired antibodies, the greater the 
suppression and by the time the maternal antibody levels have decreased to a point where 
conventional vaccines are effective at inducing active immune responses, the piglets are 
probably no longer passively protected. This leaves a window of time when the animals are 
susceptible to disease. 
Hi this experiment several vaccination strategies were attempted to try to actively 
vaccinate piglets while still under the protection of high maternally derived antibody titers. We 
vaccinated pregnant gilts with a NYVAC vaccinia vector expressing gD, and then vaccinated 
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Hg 5: Mean temperature response after challenge with virulent PRV in maternally immune 
piglets vaccinated with NYVACYgD (la), NYVAC/gB (lb), iPRV (Ic) or not vaccinated (Id). 
the piglets with either inactivated PRV vaccine or NYVAC veaors containing either gB or gD 
of PRV. As expected from past experiments using the NYVACVgD vaccine, this vaccine 
induced high VN antibody responses in the gilts which were passed to the piglets. We 
vaccinated the piglets twice because we know from previous experiments that in the case of the 
NYVAC vectors there must be a priming of the immune system from the first injection to get a 
measurable response with the second injection (Brockmeier et al 1993). This is not the case 
with the iPRV vaccine, where one vaccination is capable of stimulating a measurable immune 
response. 
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Fig 6: Mean viral shedding curves after challenge with virulent PRV in maternally immune 
piglets vaccinated with NWAC/gD (la), NYVACygB (lb), iPRV (Ic) or not vaccinated (Id). 
The piglets with maternal immunity which were vaccinated with NYVAC/gD had 
significandy higher VN antibody titers than maternally immune non-vaccinated piglets but the 
titers were significantly lower than in seronegative animals vaccinated with this vaccine. This 
suggests that there was an active immune response but it was suppressed by the presence of 
matemal immunity. Upon challenge, NYVAC/gD given to seronegative piglets protected well, 
whereas it failed to protect adequately in matemally immune piglets. It is probable that the 
immune response to gD was diminished by antibodies to gD passed to piglets in the colostrum 
of the gilts. Glycoprotein gD appears to be an especially good inducer of virus neutralizing 
antibodies and previous studies have shown no diminished antibody response to NYVAC 
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recombinants when animals with existing NYVAC antibody titers were vaccinated multiple 
times (Brockmeier et al 1993, Mengeling et al 1994b). 
Piglets with maternal immuniQr vaccinated with iPRV had a significantly higher mean 
antibody response than non-vaccinated maternally immune piglets but also had a significandy 
lower VN antibody response as compared to seronegative piglets given this vaccine. Unlike 
the NYVAC/gD vaccinated piglets, these piglets were protected much better against virulent 
challenge. The antibody response to gD may have been inhibited in this case, explaining the 
decreased VN antibody titers, but the other antigens of the virus are sufficient enough to induce 
a protective response. Another possibility is that the initial vaccination with this vaccine was 
blocked and that the second vaccination given when the piglets were approximately 5 weeks of 
age was more effective at stimulating an active immune response. The antibody titers induced 
in sax}negative pigs after one injection of iPRV are similar to those seen after the second 
injection in the pigs in this experiment However, the antibody titers at the time of the second 
injection were still at a level that under most circumstances interferes with active immunity 
Maternally immune piglets vaccinated with NYVAC/gB had VN antibody titers slightly 
higher than their non-vaccinated counterparts and significandy higher than the seronegative 
piglets given this vaccine. The higher titers in maternally immune vaccinated piglets may be 
due to the combination of anti-gD antibodies that were maternally derived and the anti-gB 
antibodies produced in response to the vaccine. Both seronegative and maternally immune 
piglets vaccinated with NYVACVgB were similarly well protected from virulent challenge with 
PRV. There appeared to be no inhibition of the immune response due to any passively 
acquired antibodies to the vaccinia veaor and since two different antigens of PRV were used, 
there should be active immunization with the second antigen. 
VN antibody titers at the time of challenge did not correlate well with the degree of 
protection. For example, all 3 vaccines protected similarly when given to seronegative pigs, 
yet the geometric mean titers in these groups ranged from 3.2 to 11.2. Also, even though the 
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maternally immune piglets which received NYVAC/gD had similar titers to the maternally 
immune piglets which received iPRV, and slightly higher titers than the piglets receiving 
NYVAC/gB, they were not as well protected as the latter groups. Curiously, all the non-
vaccinated piglets bom to immune dams had VN titers at the time of challenge which were 
comparable to the seronegative group receiving NYVAC/gB and yet this group of piglets was 
the most severely affected in terms of mortality, with 5 of the 6 pigs succumbing to the disease. 
These differences may indicate different immune mechanisms induced by the different antigens 
of PRV. The PRV glycoprotein gD appears to be a good inducer of neutralizing antibodies and 
it may take high levels of these antibodies to be protective. It is even possible that low levels of 
these antibodies were detrimental, such as is seen in cases of antibody-dependent enhancement 
of disease. Glycoprotein gB on the other hand seems to induce protection even though only 
low levels of neutralizing antibodies are present possibly indicating other immune mechanisms 
such as antibody-dependent cytotoxicity or cell-mediated immunity are induced by this protein. 
The results of this study indicate that protective antigens can be delivered to Hams and 
their offspring in the context of vaccinia vectored vaccines. This may circumvent the problems 
associated with active vaccination in the presence of maternally derived immunity. The 
compatibility of these vaccines with differential testing indicates the potential to use a 
combination of these 2 vaccinia recombinant PRV vaccines, or a recombinant and a 
conventional vaccine, to protect gilts and piglets alike from the effects of PRV infection, and 
reduce shedding of the virus. The principles of delivering different combinations of protective 
antigens to dam and offspring could be applied to other diseases as well. 
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CHAPTER 6. CELL-MEDIATED IMMUNITY TO VACCINIA VIRUS 
VECTORS EXPRESSING GLYCOPROTEINS 
GB AND GD OF PSEUDORABIES VIRUS 
A paper to be submitted to Veterinary Immunology and Lsimunopathology 
Susan L. Brockmeier, Michael J. Wannemuehler, Mitchell V. Palmer, and William L. 
Mengeling 
Abstract 
The humoral and cell-mediated immune response to glycoproteins gB and gD of 
pseudorabies virus (PRV) delivered by recombinant vaccinia viruses was investigated. 
Peripheral blood mononuclear cells from vaccinated pigs were isolated to examine the in vitro 
lymphocyte proliferative response to PRV antigen and sera from these pigs were tested for 
virus neutralizing antibodies to PRV. Pigs vaccinated with the recombinant gD vaccine 
responded with high virus neutralizing antibody titers approximating those of a group 
vaccinated with attenuated PRV vaccine, while pigs vaccinated with the recombinant gB 
vaccine had significant but lower virus neutralization titers. Following vaccination, only 2 pigs 
receiving the gB recombinant and 1 pig given the gD recombinant responded significantly in 
the lymphocyte proliferation assay after four injections. All 5 pigs vaccinated with the 
attenuated PRV vaccine responded with lymphocyte proliferative responses but to various 
degrees and at different time points. One pig which was vaccinated with the vaccinia/gB 
recombinant responded with a delayed type hypersensitivity (DTH) response to PRV. AH pigs 
which were vaccinated with the attenuated PRV vaccine had DTH responses to intradermal 
injections of PRV, the vaccinia/gB recombinant, and the vaccinia/gD recombinant Thus, a 
cell-mediated immune response and DTH response to gB and gD are apparently features of 
PRV infection; however, the study was unable to demonstrate cell-mediated or DTH responses 
to gB or gD delivered through a recombinant vaccinia vector. 
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1. Introduction 
Pseudorabies is an economically in^)ortant disease in swine which causes highly fatal 
central nervous system disease in young pigs and, in older swine, can cause respiratory 
disease, induce abortion, or cause subclinical latent infections (Kluge et al., 1992). Both 
humcnal and cell-mediated immunity are believed to play a role in recovery and protection from 
pseudorabies virus (PRV) infection. It is known that neutralizing antibodies provide partial 
protection fiom disease but antibodies cannot prevent infection or replication of the virus 
(Marchioli et al., 1988). Antibody responses as measured by ELISA, virus neutralization, 
ADCC and complement mediated lysis are demonstrable after vaccination and challenge but 
often do not coiielate with protection (Martin et al., 1986). Thus, it is theorized that cell-
mediated immunity may play an important role in protection from PRV infection. Further 
evidence that cellular immune responses are important in protection from PRV infection is the 
fact that after exposure to virulent virus, pigs are immune from reinfection for several months. 
Reexposure to virulent virus induces a secondary T cell response but not a secondary B cell 
response (Kimman et al., 1995). Therefore, developing a vaccine for PRV which stimulates 
cell-mediated immunity is important for maximizing protection and minimizing virus 
replication. In addition, any PRV vaccine needs to be safe and compatible with tests which can 
differentiate vaccinated from naturally infected animals in order to benefit eradication programs 
that have been implemented in many countries including the United States. 
Recentiy a new vaccinia vector was developed called NYVAC which has virulence and 
host range genes deleted from the Copenhagen strain of vaccinia virus (Tartaglia et aL, 1992). 
Previously, the protective effects of NYVAC vectored vaccines which express glycoproteins 
gB, gC, or gD of PRV have been examined in pigs. It was found that vectors expressing gB 
or gD both induced protection against PRV but only the vector expressing gD induced high 
virus neutralizing (VN) antibody titers (Brockmeieret al., 1993). It was also discovered that 
only the gB vaccine appeared able to stimulate a protective immune response in the presence of 
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maternal antibody (Brockmeier et al., 1996). Thus, there was evidence to suggest that 
different immune mechanisms were involved in protection against PRV depending upon the 
antigens expressed in the vectored vaccines. Because of these prior findings and the advantage 
of using live viral vectors for stimulating a cell-mediated as well as humoral immune response, 
the objective of this woik was to examine the humoral and cell-mediated immune response to 
glycoproteins gB and gD of PRV following vaccination with recombinant vaccinia viruses 
expressing these glycoproteins. 
2. Materials and methods 
2.1. Experimental design 
Twenty pigs seronegative for PRV were divided into 4 treatment groups (5 
pigs/group). The pigs in group 1 received an attenuated PRV vaccine. Groups 2 and 3 
received NYVAC veaored vaccines expressing gB or gD, respectively. Pigs in group 4 were 
left as sham vaccinated controls. The pigs in each of the principal groups were vaccinated 
intramuscularly (IM) 5 times except for group 3 which was vaccinated IM for the first 
vaccination then given virulent PRV oronasally followed by 3 more IM vaccinations with the 
attenuated vaccine. The pigs were vaccinated on day 7,28,56,91, and 140 of the experiment. 
Blood samples were collected weekly from weeks 0 through 6, and on weeks 8,9, 10,14, 15, 
20 and 21 of the experiment. Serum virus neutralization (VN) assays and lymphocyte 
proliferation assays using peripheral blood mononuclear cells (PBMC) and PRV as the in vitro 
stimulation antigen were perforaied with each blood sample. On week 21 the pigs were 
injected intadennally in the pinna of the ear with 0.1 ml of heat inactivated preparations of 
PRV, NYVAC or sham preparations and examined for delayed type hypersensitivity (DTH) 
response at 24 and 48 hours. Biopsies of the injection sites were taken at 48 hours, fixed in 
10% buffered formalin for 2 hours and then placed in ethanol. 
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22. Virus and cells 
The attenuated PRV vaccine used to vaccinate the pigs was a TK" and gG" strain of 
PRY and 1 ml containing 10^ plaque forming units (pfu) was administered IM at each 
vaccination. The PRV vaccine was propagated and titrated by plaque assay on an established 
porcine kidney cell line (PK-15). NYVAC recombinant viruses were propagated in the MARC 
cell line (first 3 doses) or primary chicken embryo fibroblasts Oast 2 doses) and titrated on 
MARC cells or bovine embryonic spleen cells (BESp) using median cell culture infective doses 
(CCID50) as described previously (Brockmeier et al., 1993). A 1 ml dose containing 10^-^ 
CCID50 of the NYVAC recombinant viruses was administered IM at each vaccination. 
Two ml of the Indiana-Funkhauser strain of PRV, containing 10® pfu, were 
administered oronasally to the pigs of group 1 at the second vaccination time point. This was 
also the virus used as the in vitro stimulating antigen in the lymphoproliferative assays. The 
PK-15 cell line and RPMI1640 media were used to propagate the virus and titrations were 
performed by plaque assay on PK-15 cells (Mengeling, 1991). 
Sham inoculum was prepared firom sham infected MARC cell cultures prepared in the 
same manner as virus infected cell cultures. 
Preparations used in the DTH response were heat inactivated at 56° C for 3 hours and 
consisted of lO'^ -^ CCIDso/ml of the NYVAC parent, NYVAC/gB, or NYVAC/gD 
recombinants, 10® pfu/ml of the Indiana-Funkhauser strain of PRV, or the sham inoculum 
used in vaccinating the pigs. Pigs which had been vaccinated with the NYVACygB or 
NYVAC/gD recombinants were injected with the PRV and sham preparations at separate sites 
on the ear. The pigs vaccinated with PRV were injected with all the antigen preparations and 
the sham vaccinated pigs were injected with the PRV, NYVAC parent and sham preparations at 
separate sites on the ear. 
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23. Antibody titration 
Titration of VN antibodies in the serum of pigs was perfonned using PK-15 cells as 
previously described (Mengeling, 1991). 
2.4. Lymphocyte proliferation assay 
Blood samples were collected into EDTA tubes and then diluted with an equal volume 
of phosphate buffered saline (PBS). Ten ml of the diluted blood was layered over 5 ml of 
lymphocyte separation media (Organon Teknika) and centrifiiged at 400 x g for 30 min. 
Peripheral blood mononuclear cells were collected from the interface and washed twice in PBS. 
Cells were resuspended in 2 ml of RPMI1640 complete medium [RPMI1640 with 25 mM 
HEPES, 0.3 mg/ml L-glutamine, 5% CPSR-2 (a serum substitute from Sigma), 100 U/ml 
penicillin, 0.1 mg/ml streptomycin, 0.25 ^ig/ml amphotericin B, and 5 x 10*5 M 2-
mercaptoethanol], counted with an automated cell counter, and adjusted to a final concentration 
of 2 X 10® cells/ml in RPMI 1640 complete medium. Lymphocyte proliferation assays were 
performed in triplicate in 96-well flat bottom microtiter plates. One hundred |ji of cell 
suspension and 100 |il of antigen preparation were added to each well. Cells were cultured at 
37° C in a humidified incubator with 5% CO2, and after 4 days the cultures were pulsed with 1 
HCi pH]thymidine per well in 50 ^1 RPMI complete media. Eighteen hours later, the cells 
were harvested onto glass filter paper and transferred to scintillation vials where 1 ml of 
scintillation fluid was added to each vial. Radioactive uptake was measured using a |3-counter. 
Antigen preparations consisted of a non-stimulatory control preparation of RPMI complete 
medium, UV inactivated PRV (2 x 10® pfu/ml before inactivation) in RPMI complete medium, 
live PRV (2 X 10® pfu/ml) in RPMI complete medium, and a stimulatory control of 
concanavalin A 10 p-g/ml. The concanavalin A preparation was added 48 hours prior to 
harvesting the cells. 
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3. Results 
3.1. Antibody response 
Virus neutralizing antibody titers of serum samples taken prior to the start of the 
experiment, and at various time points after each vaccination, were determined to assess the 
humoral immune response of the pigs to the vaccines. Prior to vaccination, the sera of all the 
pigs were free of VN antibodies against PRV. Pigs in group 1 had PRV VN antibody titers 
within 7 days following the first vaccination while pigs from the the other groups did not 
develop VN antibody titers until the second immunization (Hg. 1). After the second and third 
vaccination, the pigs in groups 1 and 3 had the highest VN antibody titers and the pigs in group 
2 had low VN antibody titers. The differences in antibody titers among the vaccinated groups 
narrowed after the fourth and fifth vaccinations when groups 1-3 all had high neutralizing 
titers. The control pigs remained seronegative throughout the experiment 
32. Lymphoproliferative response 
The lymphoproliferative response of PBMC to PRV antigen was used to assess the 
cellular immune response of the pigs to the vaccines. There was a higher lymphoproliferative 
response, in general, when live PRV antigen was added to the lymphoproliferative assay 
cultures than when UV inactivated antigen was added to the cultures. However, there was 
never a response with one and not the other. The results in figures 2 - 5 are the mean counts 
per minute of the three wells in which live PRV antigen was added. 
In group 2,2 pigs (number 47 and 157) developed a lymphoproliferative response to 
PRV subsequent to the fourth vaccination with NYVAC/gB (Rg. 2). In group 3, a single pig 
(number 249) developed a lymphoproliferative response to PRV subsequent to the fourth 
vaccination with NYVACVgD (Fig. 3). 
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Fig. 1. Mean virus neutralizing antibody titers for vaccinated pigs. Group 1 was given an 
attenuated PRV vaccine, group 2 was given a NYVAC vaccinia recombinant vaccine 
expressing glycoprotein gB of PRV, and group 3 was given a NYVAC vaccinia recombinant 
vaccine expressing glycoprotein gD of PRV. The arrows denote the vaccination time points. 
In group 1, aU pigs developed a lymphoproliferative response to PRV. The magnimde 
of the response was variable among pigs as was the timing of the response (Rg. 4). None of 
the sham vaccinated pigs (group 4) developed a lymphoproliferative response to PRV at any 
point in time. (Fig, 5). 
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Fig. 2. Individual pig lymphoproliferative responses to PRV from pigs in group 2 which were 
vaccinated with a NYVAC vaccinia recombinant vaccine expressing glycoprotein gB of PRV. 
The arrows denote vaccination time points. Mean background incorporation for this group 
was 886 cpm. 
3 J. DTH response 
Delayed type hypersensitivity was used as another measure of the cell-mediated 
immune response of the pigs to the vaccines. None of the sham vaccinated pigs had any 
response to any of the antigens preparations injected intradermally at 24 or 48 hours. Likewise 
group 3 pigs, vaccinated with NYVAC/gD, had no response to the antigen preparations at 24 
or 48 hours. One pig (number 248) in group 2, vaccinated with NYVAC/gB, developed an 
erythematous, indurated swelling at the site of injection (0.5 cm). 
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Fig. 3. Individual pig lymphoproliferative responses to PRV from pigs in group 3 which were 
vaccinated with a NYVAC vaccinia recombinant vaccine expressing glycoprotein gD of PRV. 
The arrows denote vaccination time points. Mean background incorporation for this group 
was 727 cpm. 
Pigs in group 1, which had been exposed IM and oronasally to PRV, all had 
erythematous, indurated swellings at the site of injection with PRV antigen at 24 hours post 
injection (Table 1). The response to the PRV antigen was unchanged at 48 hours for 4 of the 5 
pigs in this group had while the response in pig 499 had disappeared at 48 hours. The 
NYVACVgB antigen induced a DTH response of similar magnitude and character to that of the 
PRV antigen in group 1 pigs and in pig 251 there was a larger response. All pigs in group I 
responded to the NYVACygI> antigen at 24 hours but the response was less than to PRV and 
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Fig. 4. Individual pig lympiioproliferative responses to PRV from pigs in group 1 which were 
vaccinated with an attenuated PRV vaccine, llie arrows denote vaccination time points. Mean 
background incorporation for this group was 927 cpm. 
NYVAC/gB, The response was noticeably less at 48 hours to this antigen and had disappeared 
in 3 of the 5 pigs. There was a slight response to the parent NYVAC antigen in 3 pigs at 24 
hours which persisted to 48 hours in 1 pig. None of the pigs had a response to the sham 
preparation at either 24 or 48 hours. 
Histopathological evaluation of lesions in the skin biopsies of vaccinates tested 
intraderaoally with various antigen containing preparations were consistent with delayed type 
hypersensitivity reactions in swine (Smith and Mengeling, 1977; Fritz et al., 1990). Biopsy 
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Fig. 5. Individual pig lymphoproliferative responses to PRV from pigs in group 4 which were 
sham vaccinated controls. The arrows denote vaccination time points. Mean background 
incorporation for this group was 567 cpm. 
specimens from sham injected sites were characterized by minimal inflammatory cell infiltrate 
which was limited to low numbers of lymphocytes, macrophages and eosinophils surrounding 
superficial dermal vasculature. Ussue specimens from antigen containing injection sites 
contained variable numbers of perivascular macrophages, lymphocytes and eosinophils at all 
levels of the dermis (Fig. 6). Vessels had narrow lumina surrounded by hypertrophic 
endothelial cells with pale eosinophilic cytoplasm and large oval nuclei. Inflammatory cell 
infiltrates extended deep into the subcutis surrounding glands which often contained 
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Tabid 
DTH response to various antigen preparations at 24 / 48 hrs (cm) in group 1 pigs, which were 
vaccinate with attenuated PRV 
Intradermal Antigen 
Pig PRVa NYVAC/gBb NYVAagDC NYVACd Sham® 
45 1.0/0.9 1.1/0.8 0.9/0.5 0.0/0.0 OA) 
250 0.8/0.8 1.0/1.1 0.6/0.3 0.2/0.0 0/0 
251 0.5/0.5 1.0/0.7 0.5/0.0 0.0/0.0 0/0 
496 1.0/1.0 1.1/0.8 0.8/0.0 0.3/0.4 0/0 
499 1.0/0.0 0.9/0.0 0.5/0.0 0.4/0.0 OA) 
^ Heat inactivated PRV 
^ Heat inactivated NYVAC vaccinia recombinant expressing glycoprotein gB of PRV 
c Heat inactivated NYVAC vaccinia recombinant expressing glycoprotein gD of PRV 
Heat inactivated NYVAC vaccinia virus parent strain expressing no foreign genetic material 
^ Sham preparation of cell culture medium fix)m sham inoculated cell culture 
intraluminal infiltrates of numerous neutrophils and macrophages and lymphocytes (Fig. 7). 
Severely affected specimens contained focal to multifocal areas of necrosis with dermal 
collagen degradation and infiltrates of numerous neutrophils and macrophages among granular 
eosinophilic cellular debris and pyknotic to karyorrhectic nuclear debris (Hg. 8). Lesions in all 
specimens were limited to the dermis and subcutis, with the epidermis being normal. 
4. Discussion 
Both humoral and cell-mediated immunity are believed to be important for protection 
against pseudorabies virus infection. Glycoproteins of herpesviruses are exposed as 
peplomers on the outer envelope of the virus, produced by the cell under virus control and 
expressed on the plasma membrane of infected cells. Both cell-mediated and humoral 
immunity are induced in response to these antigens. Numerous studies have shown that 
glycoproteins gB and gD are capable of stimulating humoral responses and inducing 
Fig. 6. Histological section of skin biopsy of pig 48 hours after intradermal injection of 
heat inactivated pseudorabies virus. Note perivascular infiltration of mononuclear cells. 
HE. 40x. 
Fig. 7. Histological section of skin biopsy of pig 48 hours after intradermal injection of 
heat inactivated pseudorabies virus. Note inflamatory infiltrates surrounding ^ands which 
contain intraluminal infiltrates of neutrophils, macrophages and lymphocytes. HE. 40x. 

Fig, 8. Histological section of skin biopsy of pig 48 hours after intradennal injection of 
heat inactivated pseudorabies virus. Note area of dermal collagen degradation with 
infiltrates of numerous neutrophils and macrophages and pyknodc to karyorrtiectic nuclear 
debris. HE. 40x. 
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partial protection from disease. Glycoprotein gD appears to be one of the most potent inducers 
of VN antibodies independent of the addition of complement (Marchioli et al., 1987; Ishii et 
al., 1988; Eliot et aL, 1988; Marchioli et aL, 1988; Iglesias et al., 1990; Eliot et al., 1990; 
Mukamoto et al., 1991; Matsuda-Tsuchida et al., 1992; Tsuda et al., 1992; Riviere et al., 
1992; van der Leek et al., 1994; Ganne et al., 1994; Adam et al., 1994). Monoclonal and 
polyclonal antibodies to gB have neutralizing activity against PRV but often the presence of 
complement is required (Iglesias et al., 1990; Nakamura et al., 1990; Tsuda et al., 1991; 
Matsuda et al., 1991, Matsuda Tsuchida et al., 1992; Nakamura et al., 1993; Xuan et al., 
1995). Whether or not the glycoproteins of PRV are important in stimulating a cell-mediated 
immune response is debatable. Studies that have tried to address this question have shown that 
lymphocytes from PRV immune pigs can proliferate in response to stimulation with either 
glycoproteins gB, gC, or gD, and gC has been implicated as an inducer of cytotoxic T cells 
(Zuckermarm et al., 1990; Zuckermaim, 1991; Kimman et al., 1995). 
Cell-mediated immunity is also believed to be important in protection against another 
herpesvirus, herpes simplex virus (HSV). With HSV there is conflicting evidence as to which 
proteins of the virus are important in inducing cell-mediated immunity. Glycoproteins are 
thought to be important because studies showed a decreased lysis of target cells infected with 
temperature sensitive mutants defective in glycoprotein production by lymphocytes of HSV 
immune mice (Lawman et al., 1980). Additionally, there is decreased lysis of target cells 
where glycoprotein synthesis is inhibited by chemical means (Carter et al., 1981). In another 
study, however, a significant proportion of cytotoxic T cells recognized target cells expressing 
immediate-early proteins of HSV (Martin et aL, 1988). Glycoproteins gB, gC and gD have all 
been shown to be important in the protective immune response to HSV. Mice vaccinated with 
vaccinia virus recombinants expressing these glycoproteins were protected from lethal 
challenge with HSV (Paoletti et al., 1984; Cremer et al., 1985; Cantin et al., 1987; Weir et al., 
1989). There has been conflicting evidence as to the nature of the immune response to these 
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glycoproteins. Most evidence supports the hypothesis that gB induces a cytotoxic T ceil 
response (Zarling et al., 1986; Blacklaws et al., 1987; McLaughlin-Taylor et al., 1988; Witmer 
et aL, 1990; Hanke et al., 1991; Bonneau et al., 1993; Nugent et al., 1994). There is evidence 
which also indicates that gD stimulates T helper cells and neutralizing antibody responses but 
not a cytotoxic T cell response (Martin and Rouse, 1987; Martin et al., 1987, Rosenthal et aL, 
1987; Blacklaws et al., 1987; Wyckoff et al., 1988). 
Prior studies have shown that both the NYVAC/gB and NYVACVgD vaccines afforded 
protection from PRV disease in pigs and that the mechanisms behind protection induced by 
each recombinant might be different (Brockmeier et al., 1993, Brockmeier et al., 1996). 
Comparing these results with results from experiments with the homologous herpes simplex 
virus glycoproteins, a hypothesis was formulated that gB may afford protection primarily 
through cell-mediated mechanisms and gD may primarily afford protection via humoral 
mechanisms. The goals of this experiment were to determine the immune mechanisms induced 
by these antigens delivered in the context of a live recombinant viral veaor. In addition, it was 
of interest to demonstrate whether or not an antigen expressed by the NYVAC vector was 
enable of stimulating a cell-mediated response as this may be an advantage for the use of 
vaccinia vectored vaccines. 
The pigs vaccinated with attenuated PRV vaccine had high VN antibody, 
lymphoproliferative, and DTH responses. This indicates that both humoral and cell-mediated 
responses were induced following PRV infection. 
Pigs vaccinated with the recombinant gD vaccine responded with high virus 
neutralizing antibody titers which were detected after two injections but only one pig responded 
with a lymphoproliferative response and only after 4 injections with the NYVAC/gD vaccine. 
None of these pigs developed a demonstrable DTH response to PRV. The pigs vaccinated 
with PRV had a lower DTH response to the NYVAC/gD intradermal antigen than to the PRV 
intradermal antigen or the NYVAC/gB intradermal antigen. These results support the 
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hypothesis that gD is a good inducer of humoral immunity and neutralizing antibodies in 
particular. 
Pigs vaccinated with the recombinant gB vaccine had lower virus neutralizadon dters 
than the pigs vaccinated with the recombinant gD vaccine or PRV, however, only 2 pigs 
responded with lymphoproliferative responses following the fourth injection. Only 1 pig, 
which was not one of the pigs which had a lymphoproliferative response, appeared to have a 
DTH response to PRV. These results do not suppon the hypothesis that the NYVAC/gB 
vaccine induces a strong cell-mediated immune response. However, all the pigs vaccinated 
with PRV did have a DTH response to NYVACygB intradermal antigen that was of similar 
magnitude to whole PRV intradermal antigen. 
There are several possible explanations for the observed results. It is possible that gB 
induces cell-mediated immunity during PRV infection but that antigens delivered via the 
NYVAC vector do not stimulate good cell-mediated response. Antigens delivered through 
vaccinia vectors have been shown to induce cell-mediated immune responses in other systems 
(Beniunk et al., 1984; Martin and Rouse, 1987; Martin et aL, 1987; McLaughlin-Taylor et al., 
1988), but perhaps the debilitated replicative properties of NYVAC make it less able to 
stimulate these responses. However, if the NYVAC/PRV recombinants are inactivated they do 
not induce as strong of a virus neutralizing antibody response as the live vector (unpublished 
data). This indicates that the vector serves as more than a subunit vaccine but activates the host 
immune response. It is also possible that even though the virus neutralizing antibody titers are 
not as high for the NYVAC/gB recombinant, this may still be its primary mode of protection. 
Additionally, other antibody mediated responses such as antibody-dependent cellular 
cytotoxicity may be playing a role. In a study measuring the ADCC responses in animals 
injected with purified glycoproteins, however, it was found that gC and not gB or gD induced 
the highest antibody-dependent cellular cytotoxicity response (Kensinger et al., 1987). 
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Finally, it is possible that the NYVACVgB recombinant does afford protection primarily by 
priming a cell-mediated response which the assays used were unable to detect 
Rom the results of this and past studies, it can be concluded that gB or gD delivered 
via a recombinant NYVAC vaccinia vector induces protection against PRV disease. Virus 
neutralizing antibodies are induced by both immunogens but convincing evidence for consistent 
induction of cell-mediated immunity was not demonstrated. However, cell-mediated immune 
responses in the form of a DTH response to both gB and gD were demonstrated in PRV 
vaccinated pigs. 
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CHAPTER 7. GENERAL CONCLUSIONS 
General Discussion 
Pseudorabies is a costly and widespread disease of swine. Ciurendy, there are 
vaccines which decrease clinical disease and reduce spread of pseudorabies by decreasing the 
amount of virus shed and by increasing the amount of virus needed to initiate an infection. 
However, there is need for improved vaccines which would overcome some of the 
shortcomings of presendy available vaccines. An optimal pseudorabies vaccine should prevent 
clinical signs of disease and the associated production losses, prevent viral replication and 
shedding, prevent latent infections, induce an immune response which is distinguishable from 
wild type viral infection by differential serologic tests, be effective at stimulating active 
immuniQr in the presence of maternally derived passive immunity, induce a balanced immune 
response of both humoral and cell-mediated responses since both are thought to be important in 
protection from disease, and be safe without risk of reversion to virulence or recombination 
with wild type virus. 
Vaccinia vectored vaccines have certain advantages which make them good candidates 
for pseudorabies vaccines. They eliminate the use of live vaccine strains which reduces the 
risk of recombination while retaining the abiliQ^ to induce cell-mediated immune responses 
which may not be induced by inactivated or subunit vaccines. They are able to be used with 
existing diagnostic tests to distinguish vaccinated from naturally infected animals and are 
compatible with developing new differential tests that may be more sensitive. Vaccinia 
vectored vaccines may allow vaccination in presence of maternal immunity and with their large 
genome can accommodate antigens from several sources yielding a multivalent vaccine [219]. 
In this study, vaccinia vectored pseudorabies vaccines were evaluated. The vaccines 
were derived from the NYVAC strain of vaccinia which has reduced virulence and replicative 
capacity for certain species, including swine. Three envelope glycoproteins of PRV were 
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chosen to be expressed by the NYVAC vector to evaluate the effectiveness of this approach. 
The choice of these glycoproteins was based on previous studies which have shown them to be 
involved in protection from virulent challenge. Several questions had to be answered. Hrst, 
were the vaccines effective at inducing a protective immune response? Two injections were 
needed for pigs to develop measurable virus neutralizing antibody responses in most cases and 
after two injections pigs were significantly protected in comparison to control pigs. In 
particular, pigs vaccinated with recombinant vaccinia expressing either gB, gD, gB and gD or 
gB, gC, and gD were protected similarly to pigs which received an inactivated PRV vaccine 
(Chapters 2 and 3) [177]. The gC recombinant was less effective at inducing virus neutralizing 
antibodies and protecting against pseudorabies disease in pigs in comparison to the gB and gD 
recombinants (Chapter 2). Of the vaccinia recombinants which express a single glycoprotein, 
the virus neutralizing antibody response in pigs given the gD recombinant was the highest and 
the response was of the same magnitude as pigs vaccinated with the inactivated PRV vaccine 
(Chapter 2). The recombinant vaccinia vaccines were unable to prevent replication of virulent 
virus or latency but they were able to decrease the amount of virus shed after challenge 
(Chapters 2, 3, 4, 5)[177]. 
Contrary to the results in pigs, the recombinant vaccinia vaccines did induce VN 
antibody responses after one injection in mice (Appendix B), In fact, the VN antibody titers 
after one injection in mice were highest in those given the gC recombinant. Following a 
second injection, the VN antibody titers were highest for the mice given the gD recombinant 
followed by the gC recombinant The gB recombinant only stimulated low levels of virus 
neutralizing antibodies even after two injections. Mice given either the gC recombinant or the 
gD recombinant were completely protected from lethal challenge with PRV. The mice given 
the gB recombinant were partially protected. This agrees with other studies which have shown 
that the immunogens important for protection in mice and pigs may be different [233]. 
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A second question addressed by this work was whether or not the vaccines were safe. 
The NYVAC strain of vaccinia has virulence and host range genes deleted with the intention of 
making the vector safer and less likely to disseminate within the animal and among animals. 
Prior experimental results demonstrated that the NYVAC vector did not replicate to completion 
in a porcine kidney cell line, PK-15. The virus infects these cells and protein is synthesized 
under the influence of vaccinia virus early gene promoters, but the virus does not undergo 
DNA synthesis or produce infectious virus progeny [262]. Further investigation of the 
replicative properties in porcine cell cultures and cell cultures from other species found that 
although NYVAC does not appear to replicate in PK-15 or a swine testicular cell line it can 
replicate in certain primary and secondary porcine cell cultures (Appendix A). NYVAC 
appears to replicate with greater efSciency in fibroblastic cell cultures versus those with a more 
cuboidal or epithelial ^pearance and to loose its ability to replicate in higher passaged porcine 
cells. NYVAC did replicate in cell lines derived from other species such as chick embryo 
fibroblasts, vero cells and MARC cells which are both derived from monkey kidneys, and 
bovine embryonic spleen cells. Although NYVAC does have the capability to replicate in 
porcine cells, there is no evidence of replication in vivo. No lesions or clinical signs were seen 
in any of the pigs vaccinated in these studies and no seronegative pigs in contact with 
vaccinated pigs ever seroconverted. We also gave the virus intraveneously to 2 pigs and with 
the exception of 1 plaque forming unit isolated 5 minutes after the initial injection, we were 
unable to reisolated the virus for the next 6 days (Appendix E). 
Further investigations focused upon the vaccine regimen to be used for induction of an 
optimal protective immune response. No significant increase in protection occured by giving 
recombinants expressing multiple glycoproteins versus recombinants that expressed only gD 
(Ch^ter 3)[177]. This may be important if other differential serologic tests are developed 
which are based on an essential glycoprotein like gB. No measurable systemic immune 
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response or protection was stimulated when the recombinant vaccines were given orally or 
intranasally [177]. 
The response to the recombinant vaccines was shown to be dose dependent The PRV 
neutralizing andbody response was significandy lower when a 10 CCID50 of recombinant 
virus expressing all three glycoproteins was administered versus 10®-^ CCID50 and there was 
no measurable response after two injections of 10^-^ CCID50 of vims (Appendix C). Although 
other studies have reported interference with active immune responses when prior vaccinia 
exposure occured [108,141], there was no indication that prior immunity to the NYVAC 
vaccinia virus had any detrimental effect on subsequent stimulation of an active immune 
response to the cloned protein. When multiple injections of the parent virus were given to pigs 
followed by the NYVACl/PRV recombinants the antibody responses were similar to those of 
pigs which had no prior exposure to the NYVAC virus (Appendix D). Also, piglets which had 
received passive immunity from dams vaccinated with the gD recombinant were able to 
respond with an active immune response to the gB recombinant that was similar to the response 
of seronegative piglets (Chapter 5). The NYVAC vector with its reduced replicative capacity 
may not induce as strong of an anti-vaccinia immune response as more virulent vaccinia 
strains. 
When the live NYVAC/gD recombinant was given to pigs combined with various 
adjuvants or as an inactivated preparation, the PRV neutralizing antibody response to the 
adjuvanted preparations was similar to that of the unadjuvanted recombinant but the antibody 
response to the inactivated preparation was lower in comparison to the live vaccinia 
recombinant (Appendix F). This indicates that it is not just the PRV glycoprotein produced in 
cell culture that is stimulating the immune response in the same manner as a subunit vaccine 
would. The live vector must produce additional protein in vivo or activate cellular mechanisms 
which enhance the immune reponse to the glycoproteins. Since we did not challenge these pigs 
we do not know if the protective response induced by these preparations was different 
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The NYVAC recombinants were able to stimulate an active immune response in piglets 
with passively acquired maternal immunity, but it depended on the recombinant used (Chapters 
4 and 5). The gB recombinant was able to stimulate an active immune response in piglets with 
passive immunity from PRV or NYVAC/gD vaccinated dams. The gD recombinant was not 
able to stimulate an adequate response in either of these circimistances. There was also an 
active response with a PRV vaccine in piglets with maternal immunity from dams vaccinated 
with NYVAC/gD. This indicates that the choice of immunogen is important. It is possible 
that the level of anti-gB antibody passed to piglets from PRV immune sows is not high enough 
to interfere with active immunity or that different mechanisms of immunity which are not 
blocked by antibodies are more important in inducing the protective response by gB. 
In these studies the NYVAC/PRV recombinant vaccines were compatible with 
differential serologic tests currendy on the market (Chapters 4 and 5)[177]. To date, there is 
no evidence that the NYVAC recombinants stimulate a measurable cell-mediated immune 
response (Chapter 6). However, as a result of low dose challenge, they may prime for a T cell 
response. There is evidence that during PRV infection gB may be a better cell-mediated 
antigen than gD. 
In summary, although the NYVAC/PRV recombinant vaccines were not able to prevent 
infection or latency of PRV, they afforded protection comparable with that of PRV vaccines 
currendy on the market These vaccines are well tolerated by the animals and there appears 
litde chance of transmission to other animals. They also offer some advantages over cunendy 
available vaccines such as elimination of attenuated PRV viral strains, ability to induce active 
immunity in the presence of passive immunity and possibly more sensitive differential testing 
c^abilities. 
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APPENDIX A. NYVAC GROWTH IN PORCINE CELL CULTURE 
Table 1. Replicatioti of NYVAC recombinant viruses in various cell cultures 
Cell culture^ (passage) Susceptibility^ CPEC Virus Spread^ 
CEF(l) ++++ ++++ 
Vero (95) -H-H- -H-++ -H-H-
MARC-145 (80) »•+++ ++++ 
BESp (4) + + f  f  ++++ M + +  
PK-15 (92) +++ - -
ST (90) ++ - -
Porcine lung (5) ++++ +-H-+ < •>•++ 
Porcine thyroid (4) +++ ++ + 
Swine testicle (fibroblastic) (2) ++++ +-H-+ +-H-+ 
Swine testicle (epithelioid) (2) -H-H- ++ -H-
Swine testicle (epithelioid) (13) +++ + + 
Porcine spleen (5) 1 M t -H-+ +++ 
Porcine kidney (5) +++ -H-+ +++ 
^Cell cultures: CEF = chick embryo fibroblasts; Vero = monkey kidney cell line; MARC-145 
= monkey kidney cell line; BESp = transformed bovine embryonic spleen cells; PK-15 = 
porcine ladney cell line; ST = swine testicular cell line 
"Relative number of cells infected with multiplicity of infection of 10 
^Cytopathic effect seen in cell cultures 
^Degree to which virus spread to other cells at multiplicity of infection of 0.1 
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APPENDK B. CHALLENGE STUDY IN MICE 
Table 1. Pseudorabies virus neutralization titers, and mortally after challenge with virulent 
PRV, in mice given various NYVAC recombinant vaccines or an attenuated PRV vaccine 
Days^ 
Vaccine 21 35 49 Mortali^ 
NYVAagB <4 4 16 1/5 
NYVAagC 32 64 64 0/5 
NYVAOgD 16 256 256 0/5 
NYVAC <4 <4 NDb 5/5 
attenuated PRV 128 16 2048 0/4 
none ND <4 ND 4/4 
^ Mice were vaccinated on day 0 and day 21, challenged with 100 LD50 of virulent PRV on 
day 35, and remaining mice euthanized on day 49 of the experiment 
^ ND = not detenninai 
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APPENDIX C. DOSE RESPONSE TO NYVAC VACCINES 
Table 1. Geometric mean (Log2) PRV neutralizing antibody titers in pigs given 2 injections of 
various doses of the NYVAC recombinant expressing PRV proteins gB, gC, and gP 
Dose Virus neutralization titer^ (Range) 
108-5 CCIDso 6.3 (4-8) 
10<5-5 CCIDso 2.2 (0-5) 
104-5 CCIDso <1 «1) 
^ Virus neutralization titer 3 weeks following the second injection, mean of 6 pigs 
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APPENDIX D. RESPONSE TO MULTIPLE DOSES OF NYVAC VACCINES 
Table 1. Experimental design schedule for vaccination of pigs with multiple doses of NYVAC 
Pig Weeks 
number 0 3 6 9 12 15 
1 ,2  NYVAC-Oa NYVAC-0 NYVAC-Sb NYVAC-3 -  NYVAC-3 
3,4 - - NYVAC-3 NYVAC-3 - NYVAC-3 
5,6 NYVAC-0 NYVAC-0 NYVAC-0 NYVAC-0 NYVAC-3 NYVAC-3 
1, 8 : : : NYVAC-3 NYVAC-3 
^ Pigs given 1 ml (10®-® CCDDso/ml) of the parent NYVAC virus containing no gene inserts 
intramuscularly 
Pigs given 1ml (10' CCDDso/ml) of the NYVAC recombinant expressing genes of 
pseudorabies glycoproteins gB, gC, and gD intramuscularly 
Table 2. Pseudorabies virus neutralizing antibody titers in pigs given multiple doses of 
NYVAC vaccines 
Pig Weeks 
number 0 3 6 9 12 15 18 
1 <2 <2 <2 <2 I6a 8 1024 
2 <2 <2 <2 <2 32 8 1024 
3 <2 <2 <2 <2 16 8 1024 
4 <2 <2 <2 <2 64 32 512 
5 <2 <2 <2 <2 <2 <2 64 
6 <2 <2 <2 <2 <2 <2 16 
7 <2 <2 <2 <2 <2 <2 1024 
8 <2 <2 <2 <2 <2 <2 32 
^ Bold indicates VN antibody titer after 2 injections of the NYVAC-3 vaccine. 
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APPENDIX E. INTRAVENEOUS ADMINISTRATION OF NYVAC 
Table 1. Rdsolarion of virus from 2 pigs given NYVAC vaccinia virus intraveneously 
whole blood buffy coat serum 
Hme I 2 1 2 I 2 
0 . - . -
5 min. - + - + 
30 min. 
1 hr. 
3 hrs. ------
7 hrs. ------
24 hrs. ------
48 hrs. ------
72 hrs. ------
144 hrs. ;; ;; ; 
Pigs were injected with 10^ CCID50 of NYVAC parent virus intraveneously which 
translated to approximately 1(P-' CCID50 per ml of blood in the animal. At the various time 
points, a 10 ml blood sample was drawn and divided into 5 ml aliquots, with one aliquot 
placed in a sodium heparin tube and the other in a serum separadon tube. Cell culture (BESp 
cells) monolayers in a 24 well plate were inoculated with 100 ^il of whole blood. The heparin 
tube was then centrifiiged and a 100 ^ sample of buffy coat was inoculated onto a well in the 
24 well plate. The serum separadon tube was centrifuged and 200 ^1 of serum was inoculated 
onto another well in the 24 well plate. Additional study determined that placing virus into the 
heparin or serum separation tubes and centrifiigation had no effect on the titer of NYVAC 
virus. 
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APPENDIX F. EFFECTS OF INACTIVATION AND ADJUVANTS ON 
HUMORAL IMMUNE RESPONSE TO THE NYVAC RECOMBINANT 
EXPRESSING GD OF PRV 
Table 1. Pseudorabies virus neutralizing antibody response to live, inactivated, and adjuvanted 
NYVAqgD 
Vaccine Pig Virus neutralization titer 
UveNYVAC/gD 1 128 
2 128 
inactivated NYVAQgD 3 8 
4 16 
UveNYVAC/gD+AlOH 5 128 
6 64 
UveNYVAagD + 7 128 
AlOH & quil A 8 128 
UveNYVAagD + 9 512 
Freund's incomplete adiuvant 10 128 
none 11 <2 
12 <2 
Pigs were vaccinated twice, intramuscularly, 3 weeks apart, with the respective vaccine 
preparations. Virus neutralization antibody titers listed are from blood samples taken 2 weeks 
after the second injection. A dose of each preparation consisted of 10^CCID50 of the 
NYVAC/gD recombinant which was given live unaltered, live with 10% AlOH added, live 
with 10% AlOH and SOOng quil A added per dose, live with 1:1 ratio of Freund's incomplete 
adjuvant, or inactivated with acetylethyleneamine. 
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